EP3247790A1 - Zellreifungsverfahren - Google Patents

Zellreifungsverfahren

Info

Publication number
EP3247790A1
EP3247790A1 EP16702763.0A EP16702763A EP3247790A1 EP 3247790 A1 EP3247790 A1 EP 3247790A1 EP 16702763 A EP16702763 A EP 16702763A EP 3247790 A1 EP3247790 A1 EP 3247790A1
Authority
EP
European Patent Office
Prior art keywords
cells
phase
stem cells
sub
oxygen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP16702763.0A
Other languages
English (en)
French (fr)
Inventor
Robert Thomas
Forhad AHMED
Rachel BAYLEY
Joanne Mountford
Katie GLEN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Scottish National Blood Transfusion Service
University of Glasgow
Loughborough University Innovations Ltd
Original Assignee
Scottish National Blood Transfusion Service
University of Glasgow
Loughborough University Innovations Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scottish National Blood Transfusion Service, University of Glasgow, Loughborough University Innovations Ltd filed Critical Scottish National Blood Transfusion Service
Publication of EP3247790A1 publication Critical patent/EP3247790A1/de
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0641—Erythrocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/01—Modulators of cAMP or cGMP, e.g. non-hydrolysable analogs, phosphodiesterase inhibitors, cholera toxin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/125—Stem cell factor [SCF], c-kit ligand [KL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/155—Bone morphogenic proteins [BMP]; Osteogenins; Osteogenic factor; Bone inducing factor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/40—Regulators of development
    • C12N2501/415—Wnt; Frizzeled
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/70—Enzymes
    • C12N2501/72—Transferases [EC 2.]
    • C12N2501/727—Kinases (EC 2.7.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/02—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from embryonic cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/45—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from artificially induced pluripotent stem cells

Definitions

  • the present invention provides processes for achieving the expansion, differentiation and maturation of differentiated stem cells to cells of the myeloid lineages in particular, reticulocytes and/or enucleated mature erythrocytes. Specifically, the invention provides scalable methods for the late stage maturation of erythrocyte precursors into a relatively pure and terminally differentiated state.
  • red blood cells from stem cells in particular human pluripotent stem cells (hPSC)
  • stem cells in particular human pluripotent stem cells (hPSC)
  • hPSC human pluripotent stem cells
  • stem cell derived red blood cells Despite the increased interest in generating stem cell derived red blood cells there has been little progress made to take the early research discoveries towards the clinic and several major obstacles to RBC differentiation remain. Specifically, these are i) the efficiency of stem cell differentiation, ii) production of definitive as opposed to primitive erythroid cells, iii) sustained amplification throughout the differentiation process and iv) enucleation and terminal maturation of differentiated cells.
  • the present invention provides methods which may be used in protocols for the production of red blood cells (erythrocytes) from stem cell sources (including induced pluripotent stem cells) to facilitate late stage maturation and in particular enucleation and terminal differentiation processes.
  • red blood cells erythrocytes
  • stem cell sources including induced pluripotent stem cells
  • Endo et al (1994: Leuk Res 18: 49-54) investigated the effect of pH on human erythroid cell lined KU-812 and K562 and found that a significantly greater proportion of cells acquire a mature erythroid phenotype when cultured at pH7.6 that when cultured at pH7.4.
  • the prior art has noted a link between the pH of cell culture conditions and effects on cell differentiation, there has been no specific disclosure of scalable methods which exploit a combination of maturation conditions/factors to facilitate the late stage maturation of l erythrocyte precursor into relatively pure and terminally differentiated reticulocytes and/or enucleated mature erythrocytes.
  • the present invention provides methods and procedures which may be applied to cells (including differentiating (or partially differentiated) cells, cells in the terminal stages of differentiation and/or differentiated cells) to facilitate the late stage maturation of those cells towards mature erythrocyte lineages - in particular towards reticulocytes and/or enucleated (anucleate) mature erythrocytes.
  • the inventors have discovered that the methods described herein are not only scalable but may be used to generate populations of reticulocytes and/or enucleated, mature erythrocytes of improved quality and/or or high purity.
  • stem cells may encompass any type of totipotent, multipotent or pluripotent cell including, for example human embryonic stem cells (- including (hESC) stem cell lines that have been derived under fully GMP compliant and licensed conditions), induced pluripotent stem (iPS) cells, stem cells derived from umbilical cord blood and/or stem cells derived from peripheral blood and/or haematopoietic/haematological tissue sources (such as bone marrow, foetal liver, menstrual blood and the like).
  • hESC human embryonic stem cells
  • iPS induced pluripotent stem
  • differentiated cells or “differentiated stem cells” is used. It should be understood that the term “differentiated” embraces cells which are in the process of differentiating and which may have one or more additional differentiation stages to progress through before reaching a desired or predetermined differentiation status or before becoming what is generally known as terminally differentiated.
  • differentiated stem cell may relate to a cell which has been differentiated from a stem cell but which is not yet, itself, terminally differentiated.
  • the methods provided by this invention may be applied to differentiating or partially differentiated (stem) cells. Differentiating cells may be in the process of being differentiated towards or into one or more differentiated or terminally differentiated (adult) cell types.
  • stem cells from which the cells subjected to the methods of this invention may be derived or differentiated may include any cell which is able to self-renew and indefinitely divide - cells of this type may be described as "immortal”.
  • stem cells when cultured under suitable conditions and/or contacted with, or exposed to, particular compounds and/or conditions, stem cells may differentiate into one or more of the specialised cell types which form embryonic and/or adult tissues.
  • Stem cells may be totipotent in nature and one of skill will appreciate that totipotent cells may be capable of generating a complete viable organism as well as any given specialised cell type. Stem cells may be pluripotent - cells of this type are not capable of generating a complete viable organism, but are able to differentiate to one or more (sometimes any) specialised cell type. As such, the present invention may be applied to cells differentiated or derived from any type of totipotent and/or pluripotent stem cell.
  • stem cells may encompass embryonic, foetal, adult and/or induced pluripotent (iPS) stem cells.
  • the term “stem cells” may further encompass progenitor cells of any type.
  • the stem cells mentioned herein may be mammalian cells; for example, the term “stem cells” may be applied to human and/or non-human stem cells of all types.
  • the methods of this invention may be applied to cells derived or differentiated from stem cells derived or obtained from, or provided by, primates, ungulates, ruminants and/or rodents (specifically, sheep, pigs, cattle, goats, horses, rats and mice).
  • Stem cells may be characterised by the presence of one or more markers selected from the group consisting of: ABCG2; ACE; ALCAM; Alkaline Phosphatase; beta-Ill Tubulin; BMP-2; BMPR-IA/ALK-3; BMPR-IB/ALK-6; BMPR-II ; E-Cadherin; CCR4; CD9; CD71 ; CD90; CD90/Thy1 ; Cripto; CXCR4; DPPA5/ESG1 ; Endoglin/CD105; FABP1 ; FABP2; FGF-4; FGF R4; FoxD3; FoxP3; Frizzled-9;GAD1/GAD67; GATA-4; GATA-6; GDF-3; Glutl ; HNF-3 beta; Integrin alpha 6/CD49f; Integrin beta 1/CD29; Lefty; MAP2; Musashi-1 ; Nanog; NCAM-L1 ; Nectin-2/CD1 12;
  • stem cell markers may each be referred to as stem cell markers and references in this specification to one or more "stem cell markers", may therefore encompass one or more of the abovementioned markers.
  • stem cell markers may be probed (using, for example antibodies or other agents capable of binding one or more of the listed stem cell markers) for the presence of one or more of the stem cell markers listed above.
  • ESC embryonic stem cells
  • hESC mammalian and/or human embryonic stem cells
  • ESCs may be derived from early stage embryos and in particular from the inner cell mass of the developing morula or blastocyst.
  • Embryonic stem cells for example those derived from embryos in the stages immediately following conception (and for a short time thereafter), may be totipotent (capable of generating a complete viable organism as well as any given specialised cell type).
  • Embryonic stem cells derived from later stage embryos i.e.
  • the present invention may be applied to cells derived or differentiated from embryonic (i.e. totipotent and/or pluripotent) stem cells.
  • hESCs and other cell lines for use as source material for cells to be subject to the methods described herein may be obtained from an embryo without destruction of the embryo, as described, for example, in Chung et al (Cell Stem Cell, vol 2, issue 2, 1 13-1 17, 2008). Stem cells may also be generated using the methods described by Chung et al., (2006) which methods involve taking a blastomere cell from an early stage embryo prior to formation of the blastocyst (at approximately the 8-cell stage) and co-culturing this cell with established stem cell lines to generate a fully competent stem cell line.
  • Stem cells obtained by the methods described by Chung et al (2006, 2008) andTachibana et al (2013, Cell 153 (6), p1228-1238 and Cell 154 (2), p465-466) may be used to establish stem cell lines which themselves may serve as sources of stem cells for use in providing cells to be subject to the methods of this invention.
  • Markers of embryonic stem cells may include, for example, ABCG2, Alkaline Phosphatase, E-Cadherin, CCR4, CD9, Cripto, DPPA5/ESG1 , FGF-4, FGF R4, FoxD3, FoxP3, GDF-3, Integrin alpha 6/CD49f, Integrin beta 1/CD29, Lefty, Nanog, Oct 3 ⁇ 4, Podocalyxin, SOX2, SPARC, SSEA-1 , SSEA-3, SSEA-4 and STAT3.
  • stem cells may also be taken to refer to the pluripotent cells derived from any of the three primary germ layers (ectoderm, mesoderm and endoderm) which develop during the process of gastrulation. Cells derived from these layers may express one or more markers which may be used as a means of identification.
  • ectoderm germ layer may express markers, including, for example, Otx2, Nestin, TP63/TP73L, beta-Ill Tubulin, SHH, and PAX6.
  • Ectoderm has the potential to form cell types such as neurons and early neuronal lineage markers include ACE, ALCAM, CD90/Thy1 , GAD1/GAD67, Glutl , MAP2, NCAM-L1 , Nectin-2/CD1 12, NeuroDI , NF-L, NF-M, ROB03, gamma- Secretase, alpha-Secretase, beta-Secretase, beta-Ill tubulin, Tyrosine Hydroxylase.
  • Neural stem cell markers include ABCG2, CXCR4, FGF R4, Frizzled-9, Musashi-1 , Nestin, Noggin, Nucleostemin, Prominin 2, SOX2, Vimentin.
  • Markers of early endodermal cells include, for example, FABP1 , FABP2, GATA-4, HNF-3 beta (collectively referred to as definitive endodermal stem cells markers) as well as those markers for primitive endoderm such as alpha-Fetoprotein, beta-Catenin, GATA-4, SOX17 and SOX7.
  • the invention may also be applied to cells differentiating, differentiated or derived from "adult” stem cells - cells of this type may be taken to be stem cells obtained from adult animals and or adult (or developed/differentiated) tissue (including adult humans and/or human (adult) tissue).
  • adult also includes stem cells derived from neonatal, infant, juvenile and/or adolescent animals.
  • Adult stem cells may be sourced from any suitable tissue, including bone marrow and/or specialised structures such as, for example hair follicles, skin, teeth and the like.
  • Stem cells from which cells to be subjected to the methods of this invention may be differentiated or derived may be obtained from a variety of sources including, for example, embryonic animals (including human embryos), said embryos being either aborted or created as part of a fertility program. Alternatively, it may be possible to obtain stem cells from established stem cell lines and thus avoiding the use of mammalian, particularly human, embryos.
  • stem cells for use as source material for differentiated cells suitable for use in the methods of this invention may be obtained from the H1 and/or RC9/1 1/12/13 cell lines.
  • the methods of Meissner & Jaenisch (2006) may be used to obtain stem cells from which suitable differentiated cells may be obtained.
  • the cdx2 gene is silenced in the donor nucleus during the process of nuclear transfer to prepare a reconstructed embryo from which a line of embryonic stem cells is derived.
  • the cdx2 gene is turned back on in the isolated blastocyst cell taken from the embryo which is used to prepare the cell line.
  • This is an example of, so-called, "alternative nuclear transfer" where the embryo is not capable of implantation but the stem cell line derived therefrom is fully competent.
  • stem cells may also encompass cells otherwise known as induced pluripotent stem cells (iPS). These are re-programmed adult somatic cells which have been modified to express certain factors (such as transcription regulators) and, as a consequence, become pluripotent and thus capable of differentiating to any other specialised cell type.
  • iPS cells particularly mammalian, for example rodent iPS stem cells, may be used as sources of cells which are suitable for application in the methods of this invention.
  • stem cells described and defined herein may be used as a source of (differentiating or differentiated) cells to be subject to the methods of this invention.
  • the invention is based on the finding that cells (in the process of) differentiating or differentiated from stem cells may be exposed to or cultured or maintained under a set of conditions (referred to hereinafter as "maturation conditions") so as to ensure further differentiation of the differentiated stem cells to mature enucleated erythrocytes and/or reticulocytes.
  • maturation conditions a set of conditions
  • the method of this invention represents an improvement over prior art methods as the instant methods yield populations of cells having greater numbers of quality reticulocytes or enucleated erythrocytes than population prepared or produced by prior art methods.
  • cell populations provided by methods according to this invention often exhibit a high purity of reticulocytes or enucleated erythrocytes.
  • the maturation conditions of the method of this invention may comprise one or more modulated physiochemical and/or environmental conditions including, for example, predetermined or modulated pH conditions, predetermined or modulated oxygen conditions and/or exposure of the cells to agitation and/or mechanical stress.
  • the maturation conditions may comprise conditions in which the differentiated (or differentiating cells) are maintained or cultured under a specific and/or predetermined pH or in which the pH under which the differentiated (or differentiating) cells are maintained or cultured is reduced from a first pH to a second different pH.
  • the maturation conditions of this invention may comprise the use of a specific or predetermined level of oxygen or conditions in (or under) which the level of oxygen is modulated from a first level to a second (different) level.
  • the maturation conditions may comprise subjecting cells to some form of agitation and/or mechanical stress.
  • the present invention provides a method of providing mature enucleated erythrocytes and/or reticulocytes, said method comprising maintaining and/or culturing differentiated stem cells under one or more maturation conditions, wherein said maturation conditions are selected from the group consisting of:
  • a method according to the first aspect may exploit one, two or all three of the specified maturation conditions.
  • the conditions may be applied concurrently (together) or separately and at different and/or overlapping times.
  • the maturation conditions may be applied continuously or continually throughout a culture protocol or at one or more specific and/or predetermined times.
  • a pH and oxygen level may be set so as to bring cells (for example differentiated and/or differentiating stem cells) to a "state of readiness" for enucleation and maturation conditions comprising mechanical stress used to affect the process of enucleation.
  • the differentiated stem cells may comprise stem cell derived haematopoietic progenitor cells or erythroid progenitor cells.
  • the invention provides a method in which the provision of mature enucleated erythrocytes and/or reticulocytes, is achieved by maintaining and/or culturing haematopoietic progenitor cells and/or erythroid progenitor cells under one or more maturation conditions, wherein said maturation conditions are selected from the group consisting of:
  • the differentiated stem cells for example the haematopoietic progenitor cells and/or erythroid progenitor cells for use in this invention may be provided or obtainable by any suitable method including, for example, those methods disclosed in PCT/GB2013/051917 (the entire contents of which is incorporated herein by reference).
  • the differentiated stem cells may be provided by methods which involve contacting stem cells with a GSK3 inhibitor and/or a phosphodiesterase inhibitor.
  • the methods described in PCT/GB2013/051917 provide for the differentiation of stem cells into erythroid cells and as such, the cells for use in this invention may be those derived from only part of the procedures described therein - from example, cell obtained from those procedures executed through to about day 10 of the methods of PCT/GB2013/051917.
  • the methods used to generate differentiate stem cells for use in this invention may comprise a first phase (phase 1 ) in which stem cells or embryoid bodies are contacted with a GSK3 inhibitor (for example Inhibitor VIII and/or CHIR99021 ) and a second phase (phase 2) in which the cells are contacted with a phosphodiesterase inhibitor (such as IBMX).
  • stem cells may undergo a degree of differentiation (initially towards cells of the mesodermal germ layer specification and later towards cells of the haematopoietic lineage); as such, cells subjected to the second phase of the methods described herein may be referred to as partially differentiated stem cells or differentiated cells.
  • the purpose of the second phase of the methods described herein is to differentiate cells produced by the first phase through haematopoietic lineages towards erythroid cells.
  • Phase 1 of the methods provided by this invention may comprise the step of contacting stem cells (or embryoid bodies formed therefrom) with a GSK3 inhibitor and one or more supplementary compounds.
  • the supplementary compounds may be selected from the group consisting of:
  • BMP4 Bone Morphogenic Protein 4
  • VEGF Vascular Endothelial Growth Factor 165
  • FGF Fibroblast Growth Factor a
  • SCF Stem Cell Factor
  • Phase 1 may comprise the step of contacting stem cells with culture media supplemented with a GSK3 inhibitor and one or more of the supplementary compounds noted above.
  • Phase 2 of the methods provided by this invention may comprise the step of contacting cells produced or generated by the phase one methods with a phosphodiesterase inhibitor and one or more supplementary compounds.
  • the one or more supplementary compounds may be selected from the group consisting of:
  • BMP4 Bone Morphogenic Protein 4
  • VEGF Vascular Endothelial Growth Factor 165
  • FGFa Fibroblast Growth Factor a
  • SCF Stem Cell Factor
  • IGF2 Insulin-like Growth Factor 2
  • TPO Thrombopoietin
  • IGF1 Insulin Growth Factor 1
  • Phase 2 may comprise the step of contacting stem cells with culture media supplemented with a phosphodiesterase inhibitor and one or more of the supplementary compounds noted above as (i)-(xvi).
  • the phase 2 methods are executed in order to provide erythroid cells - however, the methods of this invention may exploit cells which have been subjected only to part of the complete phase 2 method as described in PCT7GB2013/051917.
  • the complete phase 2 process may comprise a number of sub-phases - provided as sub-phases 2a-2g, wherein the product of sub-phase 2g is an erythroid cell.
  • the methods of this invention may exploit cells which are the product of sub-phase 2d
  • differentiated stem cells for use in this invention may be provided by the following 2-phase method.
  • Phase 1 of the 2-phase method may comprise a first sub phase (referred to herein after as “sub-phase 1 a").
  • Sub-phase 1 a may comprise the step of contacting stem cells (or embryoid bodies) with one or more compounds selected from the group consisting of:
  • BMP4 Bone Morphogenic Protein 4
  • VEGF Vascular Endothelial Growth Factor 165
  • Phase 1 of the methods may further comprise a second sub-phase (referred to hereinafter as "sub-phase 1 b") executed after sub-phase 1 a.
  • Sub-phase 1 b may comprise the step of contacting the stem cells (or embryoid bodies) with one or more compounds selected from the group consisting of:
  • BMP4 Bone Morphogenic Protein 4
  • VEGF Vascular Endothelial Growth Factor 165
  • FGF Fibroblast Growth Factor a
  • SCF Stem Cell Factor
  • cells or embryoid bodies provided or produced by phase 1 (and in particular sub-phases 1 a and 1 b) of the method may be subjected to a dissociation protocol.
  • cells or embryoid bodies provided or produced by phase 1 of the method may be mechanically or chemically dissociated, and harvested by, for example centrifugation.
  • Harvested cells may (after re- suspension) be subjected to phase 2.
  • Harvested cells may be re-suspended in suitable medium such as, for example, Stemline II.
  • cells may be plated out at around 200x10 3 cells/per well.
  • Phase 2 of the 2-phase method may comprise a first sub phase (referred to hereinafter sub-phase 2a).
  • Sub-phase 2a may comprise the step of contacting the cells or embryoid bodies provided or produced by the first phase (and specifically sub-phases 1 a and 1 b), which cells or embryoid bodies may have been subjected to dissociation and harvesting protocols, with one or more compounds selected from the group consisting of:
  • IGF2 Insulin-like Growth Factor 2
  • TPO Thrombopoietin
  • a phosphodiesterase inhibitor for example IBMX
  • Phase 2 may further comprise a second sub-phase (referred to hereinafter as "sub- phase 2b).
  • Sub-phase 2b may comprise repeating the method of sub-phase 2a - in other words, sub-phase 2b comprises the step of contacting cells subjected to sub-phase 2a with one or more of the compounds listed as (i)-(ix) immediately above.
  • the cytokines used in sub-phase 2b (compounds (i)-(ix) listed immediately above) may be supplemented with a quantity of StemRegeninl (SR1 ).
  • SR1 StemRegeninl
  • the inventors have discovered that the optional addition of SR1 during sub-phase 2b (at day 5) enhances or increases the rate of cell amplification - in particular in later stages of the protocols of this invention.
  • cells cultured using methods which exploit StemRegeninl (SR1 ) are more "sturdy" and less prone to lysis.
  • Phase 2 of the methods described herein may further comprise a third sub-phase (referred to hereinafter as "sub-phase 2c").
  • Sub-phase 2c may replicate the method of sub- phase 2a and/or 2b.
  • the cells produced by sub- phase 2b may first be harvested by, for example centrifugation.
  • the cells may be split before executing sub-phase 2c.
  • the total cell number may be kept under 1 x10 6 per ml.
  • Phase 2 of the methods described herein may comprise a fourth sub-phase (referred to herein after as sub-phase 2d).
  • Sub-phase 2d may replicate the method of sub-phase 2a.
  • Sub-phase 2d comprises the step of contacting cells provided or produced by sub-phase 2c with one or more of the compounds selected from the group consisting of:
  • SCF SCF
  • IGF2 Insulin-like Growth Factor 2
  • TPO Thrombopoietin
  • a phosphodiesterase inhibitor for example IBMX
  • the concentration of the one or more compounds used in sub-phase 2d may be half that used in sub-phase 2a.
  • the product of the method of sub-phase 2d may be differentiated stem cells which are suitable for application in the methods of this invention.
  • stem cells in order to generate differentiated (differentiating or partially differentiated) stem cells and/or haematopoietic progenitor and/or erythroid progenitor cells suitable for use in the methods of the instant invention.
  • the culture conditions applied to the differentiated stem cells may be referred to as maturation conditions.
  • the maturation conditions may comprise a predetermined pH - in other words, the methods of this invention may involve culturing or maintaining differentiated (or differentiating) stem cells in (or under conditions) which comprise a predetermined pH.
  • the predetermined pH may be selected from a pH of about 4.0 to about 7.9.
  • the maturation conditions may comprise a pH of about pH4.5, about pH5.0, about pH5.5, about pH6.0, about pH6.1 , about pH6.2, about pH6.3, about pH6.4, about pH6.5, about pH6.6, about pH6.7, about pH6.8, about pH6.9, about pH7.0, about pH7.1 , about pH7.2, about pH7.3, about pH7.4, about pH7.5 about pH7.6, about pH7.7, about pH7.8 or about pH7.9.
  • the maturation conditions may comprise the use of a pH above about pH7.4; for example at about pH7.5.
  • the maturation conditions of this invention might comprise one or more of the above listed pH values; for example, the maturation conditions may modulate between different pH levels - for example a first pH and a second pH.
  • the term "about” as used herein with reference to the pH of the maturation conditions may encompass a ⁇ 0.1 , 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9 or 0.01 , 0.015, 0.02, 0.025, 0.03, 0.035, 0.04, 0.045, 0.05, 0.055, 0.06, 0.065, 0.07, 0.075, 0.08, 0.085, 0.09 or 0.095 variation in any given pH value.
  • this invention sets out a method of providing mature enucleated erythrocytes and/or reticulocytes, said method comprising culturing differentiated (or differentiating) stem cells at a pH above about pH7.4, for example at about pH 7.5.
  • the methods of this invention may comprise subjecting cells generated or obtainable by a method described in PCT/GB2013/051917 (for example the method defined by phases 1 -2d thereof) to culture conditions which comprise a pH above about pH7.4, for example at about pH 7.5.
  • the invention further provides a method of providing mature enucleated erythrocytes and/or reticulocytes, said method comprising subjecting cells generated or obtainable by a method described in PCT/GB2013/051917 (for example the method defined by phases 1 -2d thereof) to culture conditions in which the pH is set at a pH above about pH7.4; for example at about pH7.5 .
  • differentiated stem cells for example cells which are the produce of the day 10 stage (phase 2d) of the methods described in PCT/GB2013/051917
  • the methods provided by this invention are scalable in that they can be practiced on small and large volumes of cells to provide the required number of mature, terminally differentiated reticulocytes and/or enucleated erythrocytes.
  • Mature, terminally differentiated cells of this invention may, for example, take the form of erythrocyte sized haemoglobin containing cells which are anucleate (without nuclei).
  • the mature, terminally differentiated cells of this invention may be visualised using, for example, stains such as, benzidine-giemsa stain which stains haemoglobin as red/brown and other, nucleated cells as blue. Additionally or alternatively, the mature, terminally differentiated cells may be detected through the presence or absence of certain reticulocyte and/or erythrocyte markers.
  • the presence or absence of the cell surface marker protein Glycophorin A may be used as the basis of the detection of mature terminally differentiated reticulocytes and/or erythrocytes (mature, terminally differentiated cells expressing Glycophorin A).
  • Differentiated stem cells suitable for application in this invention may be directly subjected to culture conditions which comprise a pH above about pH 7.4, for example about pH 7.5.
  • a differentiated stem cell upon attaining a suitable level or stage of differentiation, a differentiated stem cell may be immediately subjected to culture conditions which comprise a pH above about pH 7.4 (for example about 7.0).
  • cells which are the product of the day 10 protocol disclosed in PCT/GB2013/051917 that is a method comprising phase 1 to at least sub-phase 2d of the methods disclosed in PCT/GB2013/051917
  • the differentiated stem cells may be maintained or cultured for a period of time before being subjected to maturation conditions which comprise a pH above about pH 7.4 or set at about pH 7.5.
  • the period of time may be anywhere from about 0 to about 1 1 days, for example 0,
  • Cells subjected to the methods of this invention may be cultured or maintained under conditions which comprise a pH above about pH 7.4 (or set at about pH 7.5) for the duration of cell culture protocol or alternatively, for example, in the final 1 -10, for example 2-9, 3-8 or
  • the methods of this invention may be conducted at any suitable temperature - including, for example, at temperatures of about 30 S C, about 32 S C, about 34 S C, about 35
  • the term "about” may encompass a variation of ⁇ 0.1 S C, 0.15 S C, 0.2 S C, 0.25 S C, 0.3 S C, 0.35 S C,
  • the methods of this invention may be conducted in a bioreactor system.
  • a stirred tank bioreactor system For example, the methods may be conducted in a stirred tank culture array.
  • Suitable bioreactor systems will be known to those skilled in this field but may include, for example the "AMBR" systems developed by TAP Biosystems. These systems mimic the characteristics of classical bioreactors at microscale. These systems are particularly useful as they permit precise control of certain physiochemical parameters including, for example, pH and oxygen.
  • Bioreactor systems for use in this invention may take the form of agitated/shaken vessels (for example agitated bags). As explained in more detail below, the bioreactor system may be used as a means to impart mechanical stress to differentiated and/or differentiating stem cells.
  • cells suitable for application in the methods of this invention may be cultured or maintained in a bioreactor system at a predetermined pH - for example a pH above about pH 7.4 or a pH set at about pH 7.5.
  • a bioreactor system Prior to use, or seeding with cells, bioreactors for use in this invention may be primed or prepared for use.
  • suitable media for example any of media A or B as described below
  • the oxygen level within the bioreactor may also be set (perhaps to a predetermined level) as too may be the pH of the added medium.
  • the priming of the bioreactor system may further include the addition of antifoaming agents - for example, antifoam C additions may be made periodically (for example every 12 or 24 hours). Volumes, 5 ⁇ _, 10 ⁇ _, 15 ⁇ _, 20 ⁇ _ or 25 ⁇ _ of a 1 % antifoam C solution may be added. Moreover, the priming may involve the addition of sodium bicarbonate; for example 5 ⁇ _, 10 ⁇ _, 15 ⁇ _, 20 ⁇ _ or 25 ⁇ _ of a 1 ⁇ solution may be added.
  • the pH of the culture systems and/or methods of this invention may be controlled or set using techniques familiar to one of skill in this field.
  • Carbon dioxide gas and/or sodium bicarbonate may be applied to the culture system in order to set/prime, control and/or modulate the pH both during the methods of this invention and/or prior to cell seeding of a culture system.
  • the bioreactor system may be set to stir or mix the reaction components (cells + (optionally supplements) media).
  • the impeller of the bioreactor may be set to rotate at a speed of about 10, 50, 100, 200, 300, 400, 450, 500, 600 rpm.
  • the impeller may be set to rotate at about 450 rpm.
  • the speed of rotation may vary depending on the size of the reactor and volume of fluid to be stirred. As explained below, the speed of rotation may be set or adjusted in order to impart some level or levels of mechanical stress to differentiated and/or differentiating stem cells.
  • the methods of this invention may further involve predetermined oxygen conditions or modulating oxygen conditions.
  • predetermined oxygen conditions for example, as an alternative or in addition to culturing differentiated stem cells under conditions comprising a predetermined pH (for example a pH above about pH 7.4 or at about pH 7.5), the cells may be further cultured in the presence of a specific level of (dissolved) oxygen.
  • the maturation conditions exploited by the method of this invention may comprise anywhere between about 1 % and about 30% oxygen (0 2 ).
  • oxygen levels in this specification refer to the amount of dissolved oxygen in the culture media.
  • % describes the percentage of oxygen saturation of the culture media that exists relative to the oxygen content of a hypothetical culture at equilibrium under a pure oxygen atmosphere.
  • the maturation conditions may exploit a level of oxygen which is less than about 90%, 80%, 70%, 60%, 50%, 40% or 30% of atmospheric oxygen.
  • the methods of this invention may exploit a level of oxygen which is less than about 50% of atmospheric oxygen.
  • the maturation conditions may exploit a level of dissolved oxygen (i.e.
  • oxygen dissolved in the culture medium of about 2%, about 3%, about 4%, about 5%, about 6%, about 7%, about 8%, about 9%, about 10%, about 1 1%, about 12%, about 13%, about 14%, about 15%, about 16%, about 17%, about 18%, about 19%, about 20%, about 21 %, about 22%, about 23%, about 24%, about 25%, about 26%, about 27%, about 28% or about 29%.
  • the level of dissolved oxygen may be set at about 1 1 %.
  • the term "about” as used herein with reference to the oxygen level of the maturation conditions may encompass a ⁇ 0.1 %, 0.15%, 0.2%, 0.25%, 0.3%, 0.35%, 0.4%, 0.45%, 0.5%, 0.55%, 0.6%, 0.65%, 0.7%, 0.75%, 0.8%, 0.85%, 0.9% or 0.95% variation in any given 0 2 level.
  • the methods of this invention may provide a method of generating or providing mature enucleated erythrocytes and/or reticulocytes, said method comprising culturing differentiated stem cells:
  • the methods of this invention exploit modulated oxygen levels, where the oxygen level is modulated from a first oxygen level to a second oxygen level.
  • the first and/or second oxygen levels may be different with the second oxygen level being higher or lower than the first oxygen level.
  • the first and second oxygen levels may be selected from the group consisting of about 1 % oxygen, about 2% oxygen, about 3% oxygen, about 4% oxygen, about 5% oxygen, about 6% oxygen, about 7% oxygen, about 8% oxygen, about 9% oxygen, about 10% oxygen, about 1 1 % oxygen, about 12% oxygen, about 13% oxygen, about 14% oxygen, about 15% oxygen, about 16% oxygen, about 17% oxygen, about 18% oxygen, about 19% oxygen, about 20% oxygen, about 21 % oxygen, about 22% oxygen, about 23% oxygen, about 24% oxygen, about 25% oxygen, about 26% oxygen, about 27% oxygen, about 28% oxygen, about 29% oxygen and about 30% oxygen.
  • the oxygen levels of the methods of this invention may be modulated over a predetermined period of time.
  • the differentiated stem cells may initially be cultured or maintained under conditions comprising a first oxygen level. After a predetermined period of time, the oxygen level may then be modulated towards a second oxygen level. The modulation may occur in a stepwise fashion or may take place directly -i.e. without intermediate steps. It should be understood that methods which involve modulated oxygen levels may exploit a plurality of different oxygen levels.
  • the method may exploit one or more high (perhaps about 30%) oxygen level(s), one or more medium/intermediate (perhaps about 7% to about 13%, about 14%, about 15%, about 16% or about 17%, 19% or 25%) oxygen level(s) and one or more low (perhaps about 1 % or about 5%) oxygen level(s).
  • the methods may require the culture of cells at a predetermined (for example intermediate) oxygen level and a predetermined pH greater than about pH7.0 (but perhaps not higher than about pH7.9) before (perhaps after about 1 , 2, 3, 4 or 5 days) culturing the cells under lower or higher oxygen level and at about pH7.0 or lower.
  • Differentiated (or differentiating) stem cells may be subject or exposed to a predetermined oxygen level at any time during any given protocol (for example a protocol designed to yield mature erythrocyte cell lineages).
  • the predetermined oxygen level(s) may be applied continuously or continually throughout a protocol or at one or more certain specific time points.
  • the predetermined oxygen level(s) may be applied for any suitable length of time.
  • a suitable length of time may depend on the nature (and duration) of the culture protocol but may be from about 1 minute to about 30 days.
  • the time during which a predetermined oxygen level or levels may be applied may be about 15 min, about 30 min, about 1 hour, about 2 hours, about 4 hours, about 6 hours, about 8 hours, about 10 hours, about 12 hours, about 24 hours, about 48 hours, about 3 days, about 4 days, about 5 days, about 6 days, about 7 days about 8 days, about 9 days, about 10 days, about 15 days, about 20 days, about 25 days or about 30 days.
  • mechanical stress (alone or in combination with any of the maturation conditions detailed above) can be used as a means to achieve and/or improve or enhance enucleation in, for example erythroid progenitor cells.
  • Cells - for example differentiated or differentiating stem cells may be subjected to variable (or modulating) levels of mechanical stress or some constant and predetermined level of mechanical stress.
  • the cells may be subjected to some predetermined high level of mechanical stress or a predetermined low level of mechanical stress.
  • a level or levels of mechanical stress may be imparted to a cell culture by forcing or passing the culture (medium + cells) through a flow device, pump, tubing or the like.
  • mechanical stress may be created in a cell culture within a bioreactor.
  • Some bioreactors are formed and adapted such that the movement of an impeller within the bioreactor creates the mechanical stress. Without wishing to be bound by theory, the movement of an impeller through a cell culture medium may create currents, eddies, shear forces and/or fluid pinch points which contribute to a level of mechanical stress experienced by any cells within the medium.
  • a level of mechanical stress may be created controlling the speed at which a bioreactor impeller tip moves through a cell culture. Impeller tip speeds of 50-500 rpm, for example speeds of about 100-450 rpm, 150-300 rpm or 200-250 rpm may be used. As stated, the level of mechanical stress used may modulate between two or more predetermined levels of mechanical stress. Under such circumstances, and where a bioreactor is used to impart the necessary mechanical stress, variable or modulating mechanical stress used may be created via the selection (and use) of one or more different impeller speeds.
  • Cells for example differentiated stem cell or differentiating stem cells to be enucleated, may be subjected to a level or levels of mechanical stress at any point during a culture protocol.
  • mechanical stress may be applied continuously or continually throughout a culture protocol or at the beginning and/or end (terminal stages of) a culture protocol.
  • Differentiated (or differentiating) stem cells may be subjected to mechanical stress during the terminal stages of any culture protocol designed to yield mature (enucleated) erythrocyte cell lineages (including, for example enucleated erythroid progenitor cells).
  • a level or levels of mechanical stress may be applied for any suitable period of time.
  • a level or levels of mechanical stress may be applied for about 1 minute to about 10 days.
  • a level or levels of mechanical stress may be applied continuously or continually throughout or during a period spanning about 1 minute to about 30 minutes, about 1 hour, about 2 hours, about 4 hours, about 8 hours, about 12 hours, 24 hours, about 48 hours, about 3 days, about 4 days, about 5 days, about 6 days, about 7 days, about 8 days or about 9 days.
  • the invention may provide methods which exploit one of the abovementioned maturation conditions, the methods may further exploit any combination of maturation conditions detailed herein. That is, the methods may, for example exploit combinations of a predetermined pH and predetermined oxygen level, pH and mechanical stress, oxygen level and mechanical stress and/or a combination of all three of the stated maturation conditions.
  • the maturation conditions may be used concurrently (that is together) or separately and at different or overlapping times.
  • the maturation conditions may be applied at one or more time points during a cell culture protocol.
  • the conditions may each (independently) be applied continuously or continually throughout the culture protocol or at some predetermined time points during the same.
  • This invention may provide a method of providing mature enucleated erythrocytes and/or reticulocytes, said method comprising maintaining and/or culturing differentiated (or differentiating) stem cells at a pH of about pH 7.5 and at 1 1 % dissolved oxygen.
  • the method may be supplemented with the application of some level or levels of mechanical stress.
  • the differentiated or differentiating stem cells may be exposed to a pH of about 7.5 and 1 1 % dissolved oxygen for the duration of the culture protocol.
  • the maturation conditions of the methods of this invention may further comprise certain types of cell culture media optionally supplemented with one or more cytokines.
  • the methods of this invention may use Iscove's Modified Dulbecco's Media (IMDM) or Dulbecco's Modified Eagle Medium based medium.
  • IMDM Iscove's Modified Dulbecco's Media
  • Dulbecco's Modified Eagle Medium based medium iscove's Modified Eagle Medium based medium.
  • Media of this type include, for example, one or more selected from the group consisting of:
  • the methods of this invention may use Stemline II media.
  • the medium (or media) for use in this invention may be supplemented with one or more supplementary compounds selected from the group consisting of:
  • SCF Stem cell factor
  • BMP4 Bone morphogenic protein 4
  • EPO Erythropoeitin
  • Phosphodiesterase inhibitor for example, IBMX.
  • media for example Stemline II media
  • media A supplemented with one or more of the cytokines listed as (i)-(viii) above shall be referred to as media A.
  • the methods may further exploit IBIT medium, which medium comprises incomplete Iscove's medium supplemented with stable glutamine, bovine serum albumin, insulin, transferring and xeno-free component lipid mixture solution.
  • IBIT medium may be further supplemented with one or more supplementary compounds selected from the group consisting of:
  • SCF Stem cell factor
  • media B For convenience, media (For example IBIT medium) supplemented with one or more of the cytokines listed as (i)-(v) above shall be referred to as media B.
  • Medium A and/or medium B may further comprise quantities (volumes) of antifoam compounds (for example antifoam C), sodium bicarbonate and/or C0 2 . These components may be automatically added at regular or predetermined intervals and/or time points. The amounts or volumes to be added may vary and approximate quantities and volumes of these compounds are noted above with reference to the priming of the bioreactor systems used in this invention.
  • the exact quantity of supplementary compound to be added to the various media for use in this invention may vary.
  • the various final concentrations and amounts of the supplementary compounds described herein may be the final concentrations and amounts of the supplementary compounds added to the base media.
  • SCF may be used at a final concentration of anywhere between about 10ng/ml and about 60ng/ml.
  • SCF may be used at a concentration of about 10, 15, 20, 25, 30, 35, 40, 45, 50, 55 or 60 ng/ml.
  • SCF may be used at a final concentration of about 40, 45, 50 or about 55 ng/ml.
  • Stemline II media may be supplemented with about 50 ng/ml SCF.
  • SCF When used as a supplement for IBIT medium, SCF may be used at a final concentration of about 15, 17, 20 or about 25 ng/ml.
  • IBIT media may be supplemented with about 20 ng/ml SCF.
  • Bone Morphogenic Protein 4 may be used at a final concentration of about 1 , 5, 10, 15, 20 or 25 ng/ml.
  • BMP-4 may be used at a final concentration of about 6, 6.2, 6.4, 6.5, 6.6, 6.7, 6.8, 7 or 7.5 ng/ml.
  • BMP4 may be used at a final concentration of about 6.7 ng/ml.
  • the phosphodiesterase inhibitor (for example IBMX) may be used at a final concentration of about 10, 20, 23, 24, 25, 26, 27, 30, 40, 45, 50, 55, 60, 70, 80, 90 or 100 ⁇ .
  • the phosphodiesterase inhibitor (for example IBMX) may be used at a final concentration of about 50 ⁇ .
  • Hydrocortisone may be used at a final concentration of about 0.1 , 0.5, 1 , 1 .5 or 2 ⁇ Hydrocortisone may be used at a concentration of about 1 ⁇ .
  • Flt3 ligand may be used at a final concentration of about 10, 12, 15, 16, 17 or 20ng/ml.
  • Flt3 ligand may be used at a final concentration of about 16.1 , 16.2, 16.3, 16.4, 16.5, 16.6, 16.7, 16.8 or 16.9 ng/ml.
  • Flt3 ligand may be used at a final concentration of about 16.7 ng/ml.
  • IL3 may be used at a final concentration of about 6, 6.2, 6.4, 6.5, 6.6, 6.7, 6.8, 7 or 7.5 ng/ml. IL3 may be used at a final concentration of about 6.7 ng/ml.
  • IL1 1 may be used at a final concentration of about 6, 6.2, 6.4, 6.5, 6.6, 6.7, 6.8, 7 or
  • IL1 1 may be used at a final concentration of about 6.7 ng/ml.
  • IGF1 may be used at a final concentration of about 5, 10, 15, 20, 25 or 30 ng/ml.
  • IGF1 may be used at a final concentration of about 20 ng/ml.
  • EPO may be used at a final concentration of about 1 , 1 .5, 2, 2.5, 3, 3.5, 4, 4.5 or 5 U/ml. EPO may be used at a final concentration of about 3 U/ml.
  • the methods of this invention may be executed over about 1 to about 15 days.
  • the methods may be executed over about 1 to about 5, 6, 7, 8, 9, 10, 1 1 , 12, 13 or
  • the methods of this invention may comprise the use of both media A and/or B as noted above.
  • the methods of this invention may exploit only media A (that is, the protocol of this invention may be conducted using media A only).
  • the methods may exploit only media B (that is the protocol of this invention may be conducted using media B only).
  • the methods may exploit both media A and media B.
  • Differentiated stem cells may be maintained in media A for at least about 1 , 2, 3, 4 or 5 days.
  • the differentiated stem cells may be maintained in media A for at least about 4 days.
  • the cells may be cultured or maintained in medium B for about 1 to about 10 days.
  • the cells may be maintained or cultured in medium B for at least about 1 , about 2, about 3, about 4, about 5, about 6 or about 7 days.
  • the selected supplementary compounds may be added to the media at day 1 (i.e. the first day of a protocol established by this invention) and replenished (or further added) on, for example, days 2 and 4.
  • the cells may be cultured in medium B for at least about 7 days.
  • the supplementary compounds used in Medium B (noted above) may be added to the media at day 1 (i.e. day 5 of the protocol of this invention) and replenished (or further added) on at least days 5 and 7 (days 9 and 1 1 of the protocol of this invention).
  • the present invention provides a method of generating or providing mature enucleated erythrocytes and/or reticulocytes, said method comprising culturing or maintaining differentiated stem cells in culture medium A and then in culture medium B, wherein the pH of at least culture medium B is set at a pH higher than about pH 7.4, for example at about pH 7.5.
  • the methods of this invention may be conducted using a (primed) bioreactor system.
  • the differentiated (or differentiating) stem cells may be maintained or cultured under conditions which comprise a pH above about pH 7.4.
  • the differentiated stem cells may be maintained or cultured under conditions which comprise a pH of about 7.5.
  • the cells may be maintained at a level of dissolved oxygen of about 10%, about 1 1 %, about 13%, about 14%, about 15%, about 16%, about 17%, about 18%, about 19%, about 20% or about 21 %.
  • the cells may be maintained or cultured at about pH 7.5 and at a level of dissolved oxygen of about 1 1 %.
  • the present invention provides a method of generating or providing mature enucleated erythrocytes and/or reticulocytes, said method comprising culturing or maintaining differentiated stem cells in culture medium A and then in culture medium B, wherein medium A comprises a quantity of SCF, Flt3L, BMP4, IL3, IL1 1 , EPO, hydrocortisone and phosphodiesterase inhibitor; and
  • medium B comprises a quantity of SCF, IGF1 , IL3, IL1 1 and EPO;
  • media A or B have a pH of greater than about pH 7.4 (for example a pH of about 7.5).
  • the pH of either medium A or B may be modulated from a first pH to a second different pH.
  • Differentiated cells for use in this invention may be seeded into medium A and/or into a bioreactor system comprising medium A, at a density of about 1 x10 4 , 1x10 5, 1x10 6 1 x10 7 , 1 x10 8 1 x10 9 or 1x10 10 cells/ml.
  • the differentiated cells may be seeded at a density of about 1 x10 5 cells/ml.
  • the cells may be allowed to expand through the remainder of their period of culture in medium A and once (and if) transferred to medium B may be re- suspended at a density of about x10 4 , 1 x10 5 ' 1x10 6 1 x10 7 , 1 x10 8 1 x10 9 or 1x10 10 cells/ml.
  • the cells may be re-suspended at a density of about 1 x10 6 cells/ml to about 1 x10 8 cells/ml.
  • differentiated cells may adopt a suitable mature phenotype (i.e. they may appear as anucleate erythrocytes and/or reticulocytes) after about 10 days of culture (that is about 20 days after initial differentiation from stem cells).
  • the methods of this invention may be in vitro or ex vivo methods.
  • the invention provides a method of generating or providing mature enucleated erythrocytes and/or reticulocytes, said method comprising culturing or maintaining in a bioreactor system, differentiated stem cells in culture medium A for at least about 4 days, wherein culture medium A and/or B has a pH above about pH 7.4 or of about pH 7.5;
  • medium A comprises a quantity of SCF, Flt3L, BMP4, IL3, IL1 1 , EPO, hydrocortisone and phosphodiesterase inhibitor;
  • medium B comprises a quantity of SCF, IGF1 , IL3, IL1 1 and EPO and has a pH of about pH 7.0.
  • both phases of the methods of this invention - namely the phase involving culture of differentiated cells using medium A and then the subsequent culture of those cells using medium B, may occur in a bioreactor system of the type described above.
  • the bioreactor may be used to impart a level or levels of mechanical stress (or agitation) to the differentiated cells.
  • the methods may be conducted in the presence of defined and/or predetermined (or modulating) oxygen levels as described herein.
  • the present invention provides a reticulocyte and/or an erythrocyte or populations of either, produced or obtainable by the methods described herein.
  • IMDM Iscove's Modified Dulbecco's Media
  • Suitable base media may include, for example, one or more selected from the group consisting of:
  • the media of this invention may be based on Stemline II media.
  • the medium (or media) for use in this invention may be supplemented with one or more supplementary compounds selected from the group consisting of:
  • SCF Stem cell factor
  • BMP4 Bone morphogenic protein 4
  • IL1 1 Interleukin 1 1
  • EPO Erythropoeitin
  • Phosphodiesterase inhibitor for example, IBMX.
  • media for example Stemline II media
  • media A supplemented with one or more of the cytokines listed as (i)-(viii) above shall be referred to as media A.
  • the invention may further provide an IBIT based medium, which medium comprises incomplete Iscove's medium supplemented with stable glutamine, bovine serum albumin, insulin, transferring and xeno-free component lipid mixture solution.
  • the IBIT medium may be further supplemented with one or more supplementary compounds selected from the group consisting of:
  • SCF Stem cell factor
  • IGF1 Insulin Growth Factor I
  • media B For convenience, media (For example IBIT medium) supplemented with one or more of the cytokines listed as (i)-(v) above shall be referred to as media B.
  • Medium A and/or medium B may further comprise quantities (volumes) of antifoam compounds (for example antifoam C), sodium bicarbonate and/or C0 2 .
  • antifoam compounds for example antifoam C
  • sodium bicarbonate for example sodium bicarbonate
  • C0 2 a bicarbonate
  • the amounts or volumes to be added may vary and approximate quantities and volumes of these compounds are noted above with reference to the priming of the bioreactor systems used in this invention.
  • the present invention provides methods and media as described above and in the detailed description and figures which follow.
  • PCT/GB2013/051917 As explained above, the disclosure of PCT/GB2013/051917 is reproduced below. At least those parts which provide a protocol for establishing haematopoietic progenitor cells (at day 10 of the described protocol encompassing at phases 1 -2d) are useful for providing cells to be used in the methods described herein. As stated, cells prepared using the methods of PCT/GB2013/051917 may be subjected to the (bioreactor based) methods of this invention so as to facilitate late stage maturation processes and to improve the yield and quality of reticulocytes and/or enucleated erythrocytes.
  • Described herein are feeder-free culture systems and media to induce and support the differentiation of stem cells into erythroid cells.
  • Described are methods of inducing differentiation of stem cells into erythroid cells comprising the step of contacting stem cells with a GSK3 inhibitor and a phosphodiesterase inhibitor.
  • the GSK3 inhibitor may comprise a GSK3-beta (GSK3- ) inhibitor.
  • the GSK3 inhibitor may comprise a specific GSK3 inhibitor; for example the GSK3 inhibitor may be comprise a specific GSK3-P inhibitor.
  • a specific GSK3 inhibitor may bind to and/or inhibit GSK3 but may not detectably bind and/or inhibit any other kinase.
  • the GSK3 inhibitor may comprise, for example, N-(4-methoxybenzyl)-N'-(5-nitro-1 ,3- thiazol-2-yl)urea - otherwise known as Inhibitor VIII or AR-A014418.
  • the GSK3 inhibitor may be a N-(4-methoxybenzyl)-N'-(5-nitro-1 ,3-thiazol-2-yl) derivative or analogue.
  • the GSK3 inhibitor may comprise CHIR99021 or a derivative or analogue thereof.
  • the phosphodiesterase inhibitor may be 3-isobutyl-1 -methylxanthine (iso butyl methyl xanthine: (IBMX)).
  • IBMX iso butyl methyl xanthine
  • R 2 is hydrogen, alkyl, methyl or isobutyl
  • R 3 is hydrogen, alkyl or methyl
  • R 4 is hydrogen, alkyl (lower or higher alkyl - for example linear or branched C Ces or C 7 -C 10 ), phenyl, substituted phenyl, hydroxyl, methyl or (CH 2 )n-0-R 5 ;
  • R 5 is hydrogen, alkyl or methyl.
  • IBMX derivatives such as, for example, 8- MeO-IBMX - otherwise known as MMPX.
  • MMPX may have the formula:
  • the methods may exploit Inhibitor VIII and/or CHIR99021 and IBMX.
  • the inventors have discovered that the methods described herein may be used to obtain improved yields of erythroid cells from stem cells. Specifically, the inventors have discovered that methods which comprise exposing or contacting cells with the GSK3 inhibitors and phosphodiesterase inhibitors described herein, result in the generation of erythroid cells exhibiting improved quality and which are near clinical grade. Additionally, erythroid cells produced by the methods described herein have been found to be more robust than those made by prior art methods. Additionally, it should be understood that the methods described herein may exploit suspension based liquid culture systems and are thus scalable. Moreover, methods described herein achieve a degree of efficiency high enough to avoid the need for any purification step (>80% HPC at d10 and >90% erythroid series by d24).
  • the methods described herein support a considerable amplification of cell numbers as they differentiate to RBCs (up to about 350,000 fold dO-24) - this represents a considerable improvement over prior art methods, including those exploiting HoxB4 as an amplifying agent.
  • the methods described herein may be applied to human induced pluripotent stem cells (iPSC) or human embryonic stem cells - including (hESC) stem cell lines that have been derived under fully GMP compliant and licensed conditions. Cells of this type are generally referred to as "stem cells" in this specification (see the definition below).
  • stem cells subjected to the methods described herein reach the orthochromatic normoblast stage of erythropoiesis and display characteristics of definitive hematopoiesis (including the shut off of embryonic globins and expression of ⁇ globin).
  • stem cells is defined above and the same definitions applies here - i.e. the term “stem cells” may be taken to refer to any cell which is able to self renew and indefinitely divide - cells of this type may be described as "immortal”.
  • stem cells when cultured under suitable conditions and/or contacted with, or exposed to, particular compounds and/or conditions, stem cells may differentiate into one or more of the specialised cell types which form embryonic and/or adult tissues.
  • stem cell includes induced pluripotent stem cell and stem cells obtained by methods which do not involve the destruction of human embryos.
  • An erythroid cell generated by the methods described may be characterised by expression of one or more haematopoietic/erythroid markers selected from the group consisting of: CD31 ; CD34; CD36; CD41 a; CD43; CD45; CD71 ; and CD235a
  • Stem cells to be used in the methods described herein may used directly from source. Additionally or alternatively, stem cells for use may comprise stem cells which have been maintained for a period of time.
  • Stem cells which are "maintained” may be retained in a proliferative and/or pluripotent state for a period or prolonged period of time and/or over a number of passages. Maintained stem cells may remain pluripotent or retain the pluripotent phenotype while at the same time being characterised by the expression of one or more of the stem cell markers described herein.
  • the stem cells for use in the methods described herein may be maintained by subjecting stem cells to a stem cell maintenance protocol.
  • a stem cell maintenance protocol may comprise the use of media and/or substrates suitable for maintaining stem cells.
  • stem cells may be maintained in a stem cell medium such as, for example Stem Pro ® .
  • the stem cells may be maintained on a substrate such as, for example, a CELLstartTM substrate.
  • Maintained stem cells may be passaged every 1 , 2, 3, 4, 5, 6, 7, 8, 9 or 10 days.
  • the methods described herein may include the additional step of inducing stem cells, for example stem cells which have been maintained for a period of time, to form embryoid bodies.
  • stem cells may form embryoid bodies if subjected or exposed to specific conditions.
  • stem cells for example those maintained using the maintenance protocols described herein, may be transferred to culture systems comprising low adherence substrates. When cultured on, or in the presence of, a low (for example ultra-low) adherence substrate, stem cells tend to form embryoid bodies.
  • confluent monolayers of stem cells may be cut or sectioned and clumps or sections of monolayer transferred to a culture system whereupon the sections and/or clumps may be induced to form embryoid bodies.
  • hESC stem cells
  • the methods described herein may comprise first and second phases.
  • the first phase and second phases may comprise steps which progressively differentiate stem cells towards cells exhibiting characteristics of the mesodermal germ layer, cells of the haematopoietic lineage and ultimately erythroid cells.
  • the method may comprise a first phase (phase 1 ) in which stem cells or embryoid bodies are contacted with a GSK3 inhibitor (for example Inhibitor VIII and/or CHIR99021 ) and a second phase (phase 2) in which the cells are contacted with a phosphodiesterase inhibitor (such as IBMX).
  • a GSK3 inhibitor for example Inhibitor VIII and/or CHIR99021
  • a phosphodiesterase inhibitor such as IBMX.
  • a degree of differentiation initially towards cells of the mesodermal germ layer specification and later towards cells of the haematopoietic lineage
  • cells subjected to the second phase of the methods described herein may be referred to as partially differentiated stem cells or differentiated cells.
  • the purpose of the second phase of the methods described herein is to differentiate cells produced by the first phase through haematopoietic lineages towards erythroid cells.
  • Phase 1 of the methods may comprise the step of contacting stem cells (or embryoid bodies formed therefrom) with a GSK3 inhibitor and one or more supplementary compounds.
  • the supplementary compounds may be selected from the group consisting of:
  • BMP4 Bone Morphogenic Protein 4
  • VEGF Vascular Endothelial Growth Factor 165
  • FGF Fibroblast Growth Factor a
  • SCF Stem Cell Factor
  • Phase 1 may comprise the step of contacting stem cells with culture media supplemented with a GSK3 inhibitor and one or more of the supplementary compounds noted above.
  • Phase 2 of the methods may comprise the step of contacting cells produced or generated by the phase one methods with a phosphodiesterase inhibitor and one or more supplementary compounds.
  • the one or more supplementary compounds may be selected from the group consisting of:
  • BMP4 Bone Morphogenic Protein 4
  • VEGF Vascular Endothelial Growth Factor 165
  • FGFa Fibroblast Growth Factor a
  • SCF Stem Cell Factor
  • IGF2 Insulin-like Growth Factor 2
  • TPO Thrombopoietin
  • IGF1 Insulin Growth Factor 1
  • Phase 2 may comprise the step of contacting stem cells with culture media supplemented with a phosphodiesterase inhibitor and one or more of the supplementary compounds noted above.
  • phase 2 may exploit methods in which stem cells or cells differentiated therefrom, are contacted with media supplemented with EPO alone.
  • Phase 1 of the methods described herein may comprise a first sub phase (referred to herein after as “sub-phase 1 a").
  • Sub-phase 1 a may comprise the step of contacting stem cells (or embryoid bodies) with one or more compounds selected from the group consisting of:
  • BMP4 Bone Morphogenic Protein 4
  • VEGF Vascular Endothelial Growth Factor 165
  • Phase 1 of the methods described herein may further comprise a second sub-phase (referred to hereinafter as "sub-phase 1 b") executed after sub-phase 1 a.
  • Sub-phase 1 b may comprise the step of contacting the stem cells (or embryoid bodies) with one or more compounds selected from the group consisting of:
  • BMP4 Bone Morphogenic Protein 4
  • VEGF Vascular Endothelial Growth Factor 165
  • FGF Fibroblast Growth Factor a
  • SCF Stem Cell Factor
  • cells or embryoid bodies provided or produced by phase 1 (and in particular sub-phases 1 a and 1 b) of the method may be subjected to a dissociation protocol.
  • cells or embryoid bodies provided or produced by phase 1 of the method may be mechanically or chemically dissociated, and harvested by, for example centrifugation.
  • Harvested cells may (after re- suspension) be subjected to phase 2.
  • Harvested cells may be re-suspended in suitable medium such as, for example, Stemline II.
  • cells may be plated out at around 200x10 3 cells/per well.
  • Phase 2 of the methods described here may comprise a first sub phase (referred to hereinafter sub-phase 2a).
  • Sub-phase 2a may comprise the step of contacting the cells or embryoid bodies provided or produced by the first phase (and specifically sub-phases 1 a and 1 b), which cells or embryoid bodies may have been subjected to dissociation and harvesting protocols, with one or more compounds selected from the group consisting of:
  • IGF2 Insulin-like Growth Factor 2
  • TPO Thrombopoietin
  • a phosphodiesterase inhibitor for example IBMX
  • Phase 2 may further comprise a second sub-phase (referred to hereinafter as "sub- phase 2b).
  • Sub-phase 2b may comprise repeating the method of sub-phase 2a - in other words, sub-phase 2b comprises the step of contacting cells subjected to sub-phase 2a with one or more of the compounds listed as (i)-(ix) immediately above.
  • the cytokines used in sub-phase 2b (compounds (i)-(ix) listed immediately above) may be supplemented with a quantity of StemRegeninl (SR1 ).
  • SR1 StemRegeninl
  • the inventors have discovered that the optional addition of SR1 during sub-phase 2b (at day 5) enhances or increases the rate of cell amplification - in particular in later stages of the protocols described herein.
  • SR1 StemRegeninl
  • Phase 2 of the methods described herein may further comprise a third sub-phase
  • Sub-phase 2c may replicate the method of sub- phase 2a and/or 2b.
  • the cells produced by sub- phase 2b may first be harvested by, for example centrifugation.
  • the cells may be split before executing sub-phase 2c.
  • the total cell number may be kept under 1 x10 6 per ml.
  • Phase 2 of the methods described herein may comprise a fourth sub-phase (referred to herein after as sub-phase 2d).
  • Sub-phase 2d may replicate the method of sub-phase 2a.
  • Sub-phase 2d comprises the step of contacting cells provided or produced by sub-phase 2c with one or more of the compounds selected from the group consisting of:
  • IGF2 Insulin-like Growth Factor 2
  • TPO Thrombopoietin
  • a phosphodiesterase inhibitor for example IBMX
  • the concentration of the one or more compounds used in sub-phase 2d may be half that used in sub-phase 2a.
  • Phase 2 of the methods described herein may comprise a fifth sub-phase (referred to herein after as “sub-phase 2e").
  • Sub-phase 2e may comprise the step of contacting cells produced or provided by sub-phase 2d, with one or more compounds selected from the group consisting of:
  • a phosphodiesterase inhibitor for example IBMX
  • sub-phase 2e may be repeated 1 , 2, 3, 4, 5, 6, 7, 8, 9 or 10 times and the time between each repeat of sub-phase 2e may be 1 , 2 or 3 days. Preferably, sub-phase 2e may be repeated 3 or 5 times with the time between each repeat being approximately 2 days.
  • the cells may be further or additionally contacted with a quantity of pluripotin (SC1 ). For example on about day 14 and about day 16, the cells may be contacted with pluripotin (SC1 ).
  • SC1 pluripotin
  • the optional addition of pluripotin (SC1 ) during sub-phase 2e enhances or increases the rate of cell amplification in later stages of the protocols described herein.
  • cells cultured using methods involving the use of pluripotin (SC1 ) were more "sturdy" and less prone lysis.
  • Phase 2 may comprise a sixth sub-phase (referred to hereinafter as "sub-phase 2f").
  • Sub-phase 2f may comprise the step of contacting the cells produced or provided by sub- phase 2f with one or more compounds selected from the group consisting of:
  • IGF1 Insulin Growth Factor 1
  • IBIT medium may comprise, for example, Incomplete Iscove's Medium supplemented with stable glutamine, Albumin (for example human and/or (foetal) bovine serum albumin), Insulin, Transferrin and xeno-free component lipid mixture solution.
  • IBIT medium may comprise, for example, Incomplete Iscove's Medium supplemented with stable glutamine, Albumin (for example human and/or (foetal) bovine serum albumin), Insulin, Transferrin and xeno-free component lipid mixture solution.
  • Sub-phase 2f may comprise the stem of using IBIT medium supplemented with the cytokines listed as (i) to (vi) above.
  • cells provided or produced by sub-phase 2e may be harvested (perhaps by centrifugation) and plated out at a density of between about 500 x 10 3 to about 1 x 10 6 per 3ml of IBIT medium.
  • Sub-phase 2f may be repeated 1 , 2, 3 or 4 times. Moreover, each time sub-phase 2f is repeated, fresh IBIT medium and fresh compounds may be used.
  • Phase 2 of the methods described herein may comprise a seventh sub-phase (referred to hereinafter as "sub-phase 2g").
  • Sub-phase 2g may comprise the step of harvesting (perhaps by centrifugation) cells produced or generated by sub-phase 2f .
  • Sub-phase 2g may further comprise the step of maintaining (optionally harvested) cells generated or produced by sub-phase 2f in IBIT medium supplemented with EPO.
  • harvested cells produced or generated by sub-phase 2f may be maintained in IBIT supplemented with EPO for about 1 , 1 .5, 2, 2.5 or 3 days.
  • Sub-phase 2g may comprise the further step of, after maintaining cells in IBIT supplemented with EPO, maintaining the cells in IBIT alone.
  • Cells may be maintained in IBIT medium for about 3, 4, 4.5, 5, 5.5, 6, 7, 8, 9, 9.5, 10, 10.5, 1 1 , 12, 13 or 14 days.
  • Described herein are methods of inducing differentiation of stem cells into erythroid cells, said methods comprising executing phase 1 as described herein and then phase 2 as described herein, wherein phase 1 comprises sub-phases 1 a and 1 b and phase 2 comprises sub-phases 2a-2g.
  • Disclosed herein is a method of inducing differentiation of stem cells into erythroid cells, said method comprising the steps of:
  • Sub-phase 1 a may represent the first step of the methods described herein; as such, sub-phase 1 a may be executed on day 0.
  • Sub-phase 1 a may last about 1 , 2 or 3 days.
  • Sub-phase 1 a may last about 2 days.
  • Sub-phase 1 b may last about 0.5, 1 or 2 days. Sub-phase 1 b may last about 1 day.
  • Sub-phase 2a may last about 1 , 2 or 3 days. Sub-phase 2a may last about 2 days.
  • Sub-phase 2b may last about 1 , 2 or 3 days. Sub-phase 2b may last about 2 days.
  • Sub-phase 2c may last about 1 , 2 or 3 days. Sub-phase 2c may last about 2 days.
  • Sub-phase 2d may last about 0.5, 1 , 1 .5 or 2 days. Sub-phase 2d may last about 1 day.
  • Sub-phase 2e may last about 4, 5, 6, 6.5, 7, 7.5 8, 9, 10, 10.5, 1 1 , 1 1 .5, 12, 13, or 14 days. Sub-phase 2e may last about 7 days or about 1 1 days
  • Sub-phase 2f may last about 5, 6, 6.5, 7, 7.5 or 8 days. Sub-phase 2f may last about 7 days. Sub-phase 2g may last about 3, 4, 5, 6, 6.5, 7, 7.5, 8, 9, 10, 1 1 , 1 1 .5, 12, 12.5, 13, 14, 15, 16, 17, 18, 19, 20 or 21 days. Sub-phase 2g may last about 7 or about 12 days.
  • sub-phase 1 a may represent the first step of the methods described herein; as such, sub-phase 1 a may be executed on day 0 and sub-phase 1 b may be executed on about day 2.
  • Sub-phase 2a may be executed on about day 3 and sub-phase 2b may be executed on about day 5.
  • Sub-phase 2c may be executed on day 7 and sub-phase 2d may be executed on about day 9.
  • Sub-phase 2e may be executed on about day 10 and sub- phase 2f may be executed on about day 17 or on about day 21 .
  • Sub-phase 2g may be executed on about day 24 or on about day 28.
  • GSK3 inhibitors for use may be used at final concentrations of about 0.05, 0.1 , 0.2, 0.3, 0.4, 0.5, 1 , 1 .5, 2, 2.5, 3, 4 or 5 ⁇ .
  • Inhibitor VIII may be used at a final concentration of about 2 ⁇ in both sub-phases 1 a and 1 b of the methods described herein.
  • CHIR99021 may be used at a final concentration of about 0.2 ⁇ in sub-phases 1 a and 1 b of the methods outlined above.
  • Bone Morphogenic Protein 4 may be used at a final concentration of about 1 , 5, 10, 15, 20 or 25 ng/ml.
  • BMP-4 may be used at a final concentration of about 5, 6, 7, 8, 9, 10, 1 1 , 12, 13, 14 or 15 ng/ml.
  • BMP4 may be used at a final concentration of about 10 ng/ml.
  • BMP 4 may be used at a final concentration of about 15, 17.5, 20, 22.5 or 25 ng/ml.
  • BMP-4 may be used at a final concentration of about 20 ng/ml.
  • BMP4 may be used at a final concentration of about 5, 7, 10, 12 or 15 ng/ml. In sub-phase 2d, BMP4 may be used at a final concentration of about 10 ng/ml. In sub-phase 2e, BMP4 may be used at a final concentration of about 6, 6.2, 6.4, 6.5, 6.6, 6.7, 6.8, 7 or 7.5 ng/ml. In sub-phase 2e, BMP4 may be used at a final concentration of about 6.7 ng/ml.
  • VEGF may be used at a final concentration of about 5, 10, 12.5, 15, 17.5, 20, 25, 30 or 35 ng/ml.
  • VEGF may be used at a final concentration of about 10ng/ml whereas in sub-phase 2a, VEGF may be used at a final concentration of about 30ng/ml.
  • VEGF may be used at a final concentration of about 15 ng/ml.
  • Wnt3A and/or Wnt5A may be used at a final concentration of about 5, 7.5, 10, 12.5 or 15 ng/ml. In sub-phases 1 a and 1 b, Wnt3A and/or Wnt5A may be used at a final concentration of about 10 ng/ml.
  • Activin A may be used at a final concentration of about 1 , 2, 3, 4, 5, 6, 7, 8, 9 or 10 ng/ml. In sub-phases 1 a and 1 b, ActivinA may be used at a final concentration of about 5 ng/ml.
  • FGFa may be used at a final concentration of about 5, 7.5, 10, 12.5 or 15 ng/ml. In sub-phases 1 b, 2a, 2b and 2c FGFa may be used at a final concentration of about 10 ng/ml. In sub-phase 2d, FGFa may be used at a final concentration of about 5 ng/ml.
  • SCF may be used at a final concentration of about 10, 14.5, 15, 15.5, 19.5, 20, 20.5 25, 29.5, 30 and 30.5 ng/ml.
  • SCF may be used at a final concentration of about 30 ng/ml.
  • SCF may be used at a final concentration of about 15 ng/ml.
  • SCF may be used at a final concentration of about 20 ng/ml.
  • IGF2 may be used at a final concentration of about 1 , 2, 3, 4, 4.5, 5, 5.5, 7.5, 10, 12.5 or 15 ng/ml. In sub-phases, 2a, 2b and 2c, IGF2 may be used at a final concentration of about 10 ng/ml. In sub-phase 2d, IGF2 may be used at a final concentration of about 5 ng/ml.
  • TPO may be used at a final concentration of about 1 , 2, 3, 4, 4.5, 5, 5.5, 7.5, 10, 12.5 or 15 ng/ml.
  • TPO may be used at a final concentration of about 10 ng/ml.
  • TPO may be used at a final concentration of about 5 ng/ml.
  • Heparin may be used at a final concentration of about 1 , 1 .5, 2, 2.5, 3, 3.5 4, 4.5 or 5 ng/ml.
  • Heparin may be used at a final concentration of about 5 ng/ml.
  • Heparin may be used at a final concentration of about 2.5 ng/ml.
  • the phosphodiesterase inhibitor (for example IBMX) may be used at a final concentration of about 10, 20, 23, 24, 25, 26, 27, 30, 40, 45, 50, 55, 60, 70, 80, 90 or 100 ⁇ .
  • the phosphodiesterase inhibitor for example IBMX
  • the phosphodiesterase inhibitor for example IBMX
  • the phosphodiesterase inhibitor for example IBMX
  • the phosphodiesterase inhibitor for example IBMX
  • the phosphodiesterase inhibitor for example IBMX
  • ⁇ -estradiol may be used at a final concentration of about 0.1 , 0.15, 0.2, 0.25, 0.3, 0.35, 0.4, 0.45, 0.5, 0.6, 0.7, 0.8, 0.9 or 1 ng/ml.
  • 1 b, 2a, 2b and 2c ⁇ -estradiol may be used at a final concentration of about 0.4 ng/ml.
  • ⁇ -estradiol may be used at a final concentration of about 0.2 ng/ml.
  • Hydrocortisone may be used at a final concentration of about 0.1 x10 "6 M, 0.2x10 “6 M, 0.5x10 “6 M, 1 x10 “6 M, 2x10 “6 M, 3x10 “6 M, 4x10 “6 M, 5x10 “6 M, 6x10 “6 M, 7x10 “6 M, 8x10 “6 M, 9x10 " 6 M or 10x10 “6 . Hydrocortisone may be used at a concentration of about 1 x10 "6 M.
  • Flt3 ligand may be used at a final concentration of about 30, 40, 45, 50, 55 ng/ml. In sub-phase, 2e, Flt3 ligand may be used at a final concentration of about 50 ng/ml.
  • IL3 may be used at a final concentration of about 6, 6.2, 6.4, 6.5, 6.6, 6.7, 6.8, 7 or 7.5 ng/ml. In sub-phase 2e and 2f, IL3 may be used at a final concentration of about 6.7 ng/ml.
  • IL1 1 may be used at a final concentration of about 6, 6.2, 6.4, 6.5, 6.6, 6.7, 6.8, 7 or 7.5 ng/ml. In sub-phase 2e and 2f, IL1 1 may be used at a final concentration of about 6.7 ng/ml.
  • IGF1 may be used at a final concentration of about 5, 10, 15, 20, 25 or 30 ng/ml. In sub-phase 2f, IGF1 may be used at a final concentration of about 20 ng/ml.
  • EPO may be used at a final concentration of about 1 , 1 .5, 2, 2.5, 3, 3.5, 4, 4.5 or 5 U/ml.
  • EPO may be used at a final concentration of about 2 U/ml.
  • EPO may be used at a final concentration of about 4 U/ml.
  • StemRegeninl may be used at a final concentration of about 0.1 -10 ⁇ .
  • a final concentration of 0.1 , 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1 , 1 .5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5, 8, 8.5, 9, 9.5 or 10 ⁇ may be used in sub-phase 2b.
  • a final concentration of about 1 ⁇ StemRegenin (SR1 ) is used.
  • Pluripotin (SC1 ) may be used at a final concentration of about 100-1000 nM. 0.1 -
  • nM 10 ⁇ .
  • a final concentration of 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, 850, 900, 950 or 1000 nM may be used in sub-phase 2e.
  • a final concentration of about 250 nM or about 500 nM Pluripotin (SC1 ) is used.
  • nM Pluripotin For example, on about day 14 of sub-phase 2e, about 500 nM Pluripotin (SC1 ) may be added. On about day 16, about 250 nM Pluripotin maybe added.
  • concentrations and amounts of the various supplementary compounds indicated above may be the final concentrations/amounts of each compound in a culture medium.
  • IMDM Iscove's Modified Dulbecco's Media
  • Dulbecco's Modified Eagle Medium based medium include, for example, one or more selected from the group consisting of:
  • media for inducing differentiation of stem cells into erythroid cells comprising a GSK3 inhibitor and/or a phosphodiesterase inhibitor and one or more supplementary compounds selected from the group consisting of:
  • BMP4 Bone Morphogenic Protein 4
  • VEGF Vascular Endothelial Growth Factor 165
  • ActivinA ActivinA
  • FGF Fibroblast Growth Factor a
  • SCF Stem Cell Factor
  • IGF2 Insulin-like Growth Factor 2
  • TPO Thrombopoietin
  • IGF1 Insulin Growth Factor 1
  • the medium may comprise a base medium suitable for the maintenance and/or expansion of stem cells.
  • the base medium may comprise a medium suitable for the maintenance and/or expansion of stem cells.
  • Media of this type may comprise, for example, compounds and molecules which facilitate the maintenance and/or expansion of stem cells.
  • the base medium may comprise an Iscove's Modified Dulbecco's Media (IMDM) or Dulbecco's Modified Eagle Medium based medium.
  • IMDM Iscove's Modified Dulbecco's Media
  • Dulbecco's Modified Eagle Medium based medium a medium suitable for the maintenance and/or expansion of stem cells.
  • the base medium may comprise one or more selected from the group consisting of:
  • Suitable base media may be serum free.
  • the base medium may comprise, for example, Stemline ® II medium (Sigma-Aldrich Co. LLP).
  • the methods described herein may utilise any IMDM or DMEM based media but by way of example, the methods may utilise media comprising Stemline ® II. Media of this type may be suitable for use in any of sub-phases 1 a, 1 b, 2a, 2b, 2c, 2d and/or 2e.
  • the base medium may comprise IBIT medium itself comprises Incomplete Iscove's medium supplemented with stable glutamine, bovine serum albumin, insulin, transferring and xeno-free component lipid mixture solution.
  • a medium for inducing differentiation of stem cells into erythroid cells and/or for use in a method of inducing differentiation of stem cells into erythroid cells may comprise a GSK3 inhibitor and one or more compounds selected from the group consisting of:
  • BMP4 Bone Morphogenic Protein 4
  • VEGF Vascular Endothelial Growth Factor 165
  • FGF Fibroblast Growth Factor a
  • SCF Stem Cell Factor
  • IGF2 Insulin-like Growth Factor 2
  • TPO Thrombopoietin
  • IGF1 Insulin Growth Factor 1
  • a medium for inducing differentiation of stem cells into erythroid cells and/or for use in a method of inducing differentiation of stem cells into erythroid cells may comprise:
  • BMP4 Bone Morphogenic Protein 4
  • VEGF Vascular Endothelial Growth Factor 165
  • FGFa Fibroblast Growth Factor a
  • SCF Stem Cell Factor
  • a medium for inducing differentiation of stem cells into erythroid cells and/or for use in a method of inducing differentiation of stem cells into erythroid cells may comprise:
  • VEGF Vascular Endothelial Growth Factor 165
  • a medium of the type described immediately above may be used in sub-phase 1 a of the methods described herein.
  • a medium for inducing differentiation of stem cells into erythroid cells and/or for use in a method of inducing differentiation of stem cells into erythroid cells may comprise:
  • BMP4 Bone Morphogenic Protein 4
  • VEGF Vascular Endothelial Growth Factor 165
  • FGF Fibroblast Growth Factor a
  • SCF Stem Cell Factor
  • a medium of the type described immediately above may be used in sub-phase 1 b of the methods described herein.
  • a medium for inducing differentiation of stem cells into erythroid cells and/or for use in a method of inducing differentiation of stem cells into erythroid cells may comprise one or more compounds selected from the group:
  • BMP4 Bone Morphogenic Protein 4
  • VEGF Vascular Endothelial Growth Factor 165
  • FGFa Fibroblast Growth Factor a
  • SCF Stem Cell Factor
  • IGF2 Insulin-like Growth Factor 2
  • TPO Thrombopoietin
  • a medium for inducing differentiation of stem cells into erythroid cells and/or for method of inducing differentiation of stem cells into erythroid cells may comprise
  • BMP4 Bone Morphogenic Protein 4
  • VEGF Vascular Endothelial Growth Factor 165
  • FGF Fibroblast Growth Factor a
  • SCF Stem Cell Factor
  • IGF2 Insulin-like Growth Factor 2
  • TPO Thrombopoietin
  • a medium of the type described immediately above may be used in sub-phases 2a, 2b, 2c and 2d of the methods described herein.
  • a medium for inducing differentiation of stem cells into erythroid cells and/or for use in a method of inducing differentiation of stem cells into erythroid cells may comprise:
  • BMP4 Bone Morphogenic Protein 4
  • a medium of the type described immediately above may be used in sub-phase 2e of the methods described herein.
  • the media described above and which are suitable for use in sub-phases 1 a, 1 b, 2a, 2b, 2c, 2d and 2e of the methods may further comprise Stemline ® ll.
  • a medium for inducing differentiation of stem cells into erythroid cells and/or for use in a method of inducing differentiation of stem cells into erythroid cells may comprise:
  • SCF Stem Cell Factor
  • EPO Erythropoietin
  • IGF1 Insulin Growth Factor 1
  • a medium of the type described immediately above may be used in sub-phase 2f of the methods described herein.
  • a medium for inducing differentiation of stem cells into erythroid cells and/or for use in a method of inducing differentiation of stem cells into erythroid cells may comprise Erythropoietin (EPO).
  • EPO Erythropoietin
  • a medium of the type described immediately above may be used in sub-phase 2g of the methods described herein.
  • Media suitable for use in sub-phases 2f and 2g may further comprise IBIT medium as defined above.
  • concentrations and amounts of various supplementary compounds described above may vary depending upon the application but in general, the media may contain concentrations and amounts of supplementary compounds substantially identical or similar to the concentration and amounts required in the methods described herein. Suitable concentrations and amounts of the various supplementary compounds are described in more detail above (see section discussing methods and sub- phases).
  • kits for inducing differentiation of stem cells into erythroid cells comprising one or more components selected from the group consisting of:
  • BMP4 Bone Morphogenic Protein 4
  • VEGF Vascular Endothelial Growth Factor 165
  • FGF Fibroblast Growth Factor a
  • SCF Stem Cell Factor
  • IGF2 Insulin-like Growth Factor 2
  • TPO Thrombopoietin
  • IGF1 Insulin Growth Factor 1
  • Figure 1 High purity mature erythrocytes from Day 20 of a method performed in accordance with an embodiment of this invention: ejected nuclei and erythrocyte sized haemoglobin containing cells can be seen.
  • Figure 2 Low purity erythrocytes from a higher pH (7.5) culture.
  • FIG. 3 Bioreactor Culture at pH 7.0 and 21 % 0 2 from the point the cells were received - the results show the production of highly mature cells after only 5 days.
  • Figure 4 A subsequent run employing a pH drop to 7.0 at Day 17 (7 days after receiving cells) where cells had been exposed to alternate oxygen conditions of 7%, 10%, 13%, 16% or 19% at pH 7.3 or 13% at pH 7.5, showed high quality red cell maturation upon exposure to 13%, 16% and 19% oxygen at day 21 (1 1 days after receiving cells).
  • a short 12 hour exposure to pH 7.0 at day 8 followed by reversion to pH 7.4 up to day 21 did not replicate the effect as shown in the next images (all images day 21 ).
  • Figure 5 A subsequent experiment explored the effect of dropping pH to 7.0 after 15, 17, or 19 days (after 5, 7 or 9 days in the bioreactor after transfer). The pH drop at day 5 showed good red cell maturity at day 20 (day 20 shown in images, day 24 was also observed).
  • Adherent culture (d3-10) is not required for expansion & differentiation. Histogram representative of total fold amplification of erythroid differentiation culture of hESC line H1 cultivated in the presence of Inhibitor VIII on normal tissue culture treated surface or on ultra low adherence surface between day 3 and day 10.
  • Figure 7 Effect of GSK inhibitor on phenotype at d10.
  • the presence of CD34, CD31 , CD41 and CD235a indicate that the analyzed cells are either at an hemangioblastic or shortly post hemangioblastic stage.
  • the differences observed between H1 and iPSC reflect the differential kinetics of differentiation intrinsic to these cell lines.
  • Figure 8 >90% CD235a (GlyA+) erythroid cells at d24.
  • A Flow cytometry analysis of differentiated hPSCs at day 28 in erythroid culture conditions. The presence of transferring receptor (CD71 ) on more of 80% of the cells analysed show that the cells are still in expansion phase and the presence of glycophorin A (CD235a) on more than 95% of the cells analysed while CD31 , CD34 and CD41 have disappeared (data not shown) is a good indicator of the erythroid character of the cells.
  • B Rapid Romanovski staining of a cytospin preparationof hiPSC differentiated into erythroid cells at day 28, the cells are mainly orthochromatic normoblasts.
  • Figure 9 GFs and GSK inhibitors are additive. Histogram representative of cumulative fold amplification during of erythroid differentiation culture of iPS line in absence or presence of Activin A.
  • Figure 10 InhibVIII increases cell numbers in multiple lines.
  • A-Histogram representative of total fold amplification of erythroid differentiation culture of hESC lines RC9 and H1 in absence or presence of inhibitor VIII B-Histogram representative of total fold amplification of erythroid differentiation culture of iPS line in absence or presence of inhibitor VII I, both conditions included IBMX.
  • FIG 11 A. IBMX further increases expansion. Histogram representative of cumulative fold amplification over time of erythroid differentiation culture of H1 (hESC) or hiPSC without any small molecules or with combinations of GSK3P inhibitors and IBMX using the standard option of 7 days in cytokine mix A.
  • B Histogram representative of cumulative fold amplification over time of erythroid differentiation culture of H1 (hESC) or hiPSC without any small molecule or with combinations of GSK3P inhibitors and IBMX using the prolonged period of 1 1 days in cytokine mix A.
  • Figure 12 Inh VIII + IBMX Increase key molecular markers in iPSC. Histograms representative of imRNA expression for a set of genes involved in erythropoiesis. Expression was determined by RTqPCR of differentiating hPSCs +/- Inhibitor VIII alone or Inhibitor VIII + IBMX at day 0, 10, 17 and 24 of erythroid culture.
  • Figure 13 Globins are almost exclusively fetal not embryonic. HPLC analysis of the globins produced by the differentiated hPSCs. The disappearance of haemoglobin Gower 1 ( ⁇ 2 ⁇ 2 chains) is noticeable in erythroid cells derived from iPSCs (Panel 2: B) and hESCs H1 (Panel 3: C), compared with Panel 1 (A) which exhibit a mixed expression of embryonic and fetal globins. The hPSC derived cells exhibit an HPLC profile similar to that obtained from control cells of fetal origin (panel 4: D). The difference observed in globin ⁇ chain may be due to some residual haemoglobin Portland ( ⁇ 2 ⁇ 2 chains).
  • Figure 14 Comparison of cell numbers with wnt3a vs wnt5a
  • Figure 15 Effect of SC1 + SR1 on iPSC (A) or hESC (B) amplification during differentiation
  • Figure 16 Comparison of cells at day 30 after culture +/- SR1 and SC1
  • FIG. 17 Graph A shows the average effect of different oxygen levels across a pH range; robust maturation and enucleation is achieved at oxygen levels under 50% of atmospheric oxygen (or under 1 1 % dissolved Oxygen).
  • This graph also shows culture at below pH 7.4 may lead to significantly lower enucleation. Under these lower pH conditions non-erythroid lineage cells can be seen to persist in the culture system consequently lowering the enucleated yield (data not shown).
  • Graph B shows that these effects (those shown in graph A) are non-independent; a low oxygen level may reduce the sensitivity to the detrimental effects of a low pH, and a higher pH may reduce the sensitivity to the detrimental effects of higher Oxygen. Culturing cells above about pH 7.4 and beneath about 50% atmospheric Oxygen (1 1 % dissolved oxygen) may lead to robust enucleation.
  • Figure 18 Graph A shows the increase in peak enucleation observed when cells are cultured under high vs low mechanical stress.
  • the stress in this case is created by a bioreactor impeller with a tip speed of 157mm/second (350rpm) or 236mm/second (450rpm).
  • the majority of the mechanical effect is on the terminal enucleation event, rather than any accumulated effect through culture; this is shown in graph B where cells from a non- mechanically stressed system are transferred to the mechanically stressed system during the enucleation phase (after 19 days). Two days later a 17 percentage point improvement in enucleation is observed, and this advantage is maintained over the subsequent week.
  • the effect of mechanical agitation may be relative to the underlying level of enucleation in the culture and the absolute effect is therefore not independent of pH and oxygen. Without wishing to be bound by theory, this may represent an economic advantage as it will enable greater control of population purity at harvest and enables peak enucleation levels to be achieved significantly closer to peak cell yield.
  • a method of this invention which exploits a predetermined pH level (for example a pH greater than about pH 7.4 (for example about pH 7.5) and an oxygen level at or under 50% of atmospheric oxygen (or at or under about 1 1 % dissolved oxygen) may be supplemented with some exposure to a level or levels of mechanical stress. In combination with the control of the pH and 0 2 levels, this may further increasing the purity of an enucleated erythrocyte population produced from pH/02 control.
  • AMBR stands for Advanced Micro Bioreactor.
  • the system is a proprietary platform from TAP Bio-systems designed to provide a scaled down model of the most common scaled up production system for biologic products: a stirred tank bioreactor.
  • pluripotent cell derived erythroid progenitor cells in a multi 10ml vessel, scaled down, stirred tank culture array (Advanced Micro Bioreactor: AMBR) held at pH 7.0 develop a very mature terminally differentiated phenotype.
  • AMBR Advanced Micro Bioreactor
  • the effect of the pH drop may be dependent on the maturation state of the cells, and potentially through this or alternate mechanism, interdependent with any alteration to the media composition used in the methods to generate differentiated stem cells for use.
  • AMBRTM vessels Prior to cell seeding, AMBRTM vessels (TAP Biosystems, Royston, UK) were filled with 14ml_ of medium and stabilised for temperature (37 °C), d0 2 (16%, 21 %) and pH (7.3). Automated antifoam C additions (20 ⁇ _ of 1 % solution, Sigma-Aldrich) were made every 24hr. Automated sodium bicarbonate additions (20 ⁇ _ of 1 M solution, Sigma-Aldrich) and C0 2 gassing maintained culture set pH (automatically monitored every 2hr and adjusted as required). An impeller speed of 450 rpm was used to maintain the cells in stirred suspension in the AMBR system.
  • Day 10 cells i.e. received cells
  • Day 10 cells were inoculated into the pre-conditioned AMBRTM vessels.
  • Cells were cultured at an initial density of 1 x10 5 cells/ml in Stemline II media (Sigma-Aldrich) supplemented with cytokine mix A: SCF (50ng/ml_, Flt3L (16.7ng/ml_, BMP4, IL3, IL1 1 (all 6.7ng/ml_), EPO (3 Units/mL and hydrocortisone 1 uM) and reagent-x (IBMX; 50 uM). Physicochemical conditions were maintained as above. Cultures were supplemented with cytokine mix A on days 2 and 4.
  • Cells were visualised by sampling from the bioreactors after about day 20 (i.e. 10 days after start of maturation protocol of this invention). Cell samples were processed onto slides with Cytospin and stained with benzidine-Giemsa stain (Haemaglobin shows red/brown other cells and nuclei show blue).
  • hPSC human pluripotent stem cells
  • hPSC confluent hPSC are cut into squares with the EZpassage tool (Life Technologies) and plated at 500x10 3 /well on Ultra low adherence six well plates (Corning) in 3ml/well of Stemline II (Sigma) to allow them to form embryoid bodies (EBs).
  • BMP4 Bone Morphogenic Protein 4
  • VEGF Vascular Endothelium Growth Factor 165
  • Wnt3A and/or Wnt5A
  • ActivinA 5ng/ml
  • Inhibitor VIII 2 ⁇
  • GSK3 Inhibitor VIII is a specific name for the Merck product (361549), it is also called AR- A014418 or N-(4-Methoxybenzyl)-N'-(5-nitro-1 ,3-thiazol-2-yl)urea
  • cytokines On day 2 of differentiation (48 hours old EBs), a new set of cytokines is added in 0.5ml/well of Stemline II.; BMP4 (20ng/ml), VEGF (30ng/ml), Wnt3A (and/or Wnt5A) (10ng/ml), ActivinA (5ng/ml), Inhibitor VIII (2 ⁇ ), Fibroblast Growth Factor a (FGFa) (10ng/ml), Stem Cell Factor (SCF) (20ng/ml) and ⁇ -Estradiol (0.4ng/ml).
  • BMP4 (20ng/ml)
  • VEGF (30ng/ml)
  • Wnt3A and/or Wnt5A
  • ActivinA (5ng/ml)
  • Inhibitor VIII (2 ⁇
  • FGFa Fibroblast Growth Factor a
  • SCF Stem Cell Factor
  • NB Given cytokine concentrations are always the final concentrations of freshly added cytokines - e.g. when cells are fed rather than undergoing complete media change, we add 0.5ml of 6x cytokines to 2.5ml already in well to give final total volume of 3ml with 1 x cytokines.
  • the cells are harvested, centrifuged 3 minutes at 1200 rpm and resuspended in fresh Stemline II medium supplemented with the same set of cytokines as day 3. If the number of cells is above 500x10 3 , it is advisable to split the culture as any drastic depletion or major pH increase of the medium can have major repercussion on the differentiation efficiency. From day 7 to day 10 of differentiation the cell density should be closely monitored in order to maintain the cell number under 10 6 per ml by adding fully supplemented media and splitting into additional wells if required.
  • cytokines On day 9 of differentiation a half dose of day 3 cytokines is added in 0.5 ml/well of Stemline II such that final concentrations of fresh cytokines are half those stated for day 3.
  • the cells are centrifuged 3 minutes at 1200 rpm then re-plated in erythroid liquid culture conditions, i.e. the cells are plated at a density of 100x10 3 cells/well in 3ml/well of Stemline II supplemented with the following cytokines:
  • IBIT medium Composed of Incomplete Iscove's Medium with stable glutamine (Biochrom AG), 1 % Bovine Serum Albumin (Life Lechnologies or Sigma), 10ug/ml Insulin, 200ug/ml Transferrin (both from Sigma) and xeno free component lipid mixture solution 200x (Peprotech)) supplemented with the following cytokines: Hydrocortisone 10 "6 M, SCF (20ng/ml), Insulin Growth Factor 1 (IGF1 ) (20ng/ml), Interleukin 3 (IL3) (6.7ng/ml), IL1 1 (6.7ng/ml) and Erythropoietin (EPO) 2U/ml. From day 17 or 21 to day 24 or
  • the cells are centrifuged 3 minutes at 1200 rpm then re-plated at a density of 500-1000 x10 3 in fresh IBIT supplemented with 4U/ml of EPO for 2 days, followed by 5 to 10 days in IBIT medium alone.
  • the culture medium is refreshed every 2 days by addition of fresh IBIT medium.
  • cells were analysed by flow cytometry to evaluate their hematopoietic and erythroid characteristics.
  • the antibodies used were directed against CD31 , CD34, CD36, CD41 a, CD43, CD45, CD71 and CD235a (also known as glycophorin A) (BD Biosciences and eBioscience) and the cells were analysed with a BD FACSCalibur flow cytometer (BD Biosciences).
  • the gene panel was selected to comprise genes known to be expressed at various stages of erythropoiesis in order to evaluate the degree of differentiation of the hPSCs.
  • RBCs from hPSC described herein is a sequential differentiation process aimed at mimicking in vivo erythroid development, in order to obtain a final product similar to and consistent with the biological functions of in vivo derived RBCs.
  • hPSCs are encouraged to form EBs and are directed towards mesodermal germ layer specification through a balanced cocktail of BMP4, VEGF, Wnt3A (Wnt5A) and Activin A.
  • BMP4 vascular endothelial growth factor
  • Wnt3A Wnt5A
  • Activin A Several dosages were tested in order to determine the best combination of cytokines to optimize conversion efficiency.
  • hematopoietic lineage differentiation is primed through the increase of BMP4 and VEGF and the addition of SCF, FGFa and ⁇ -Estradiol.
  • the cells are further directed towards hematopoietic differentiation through the addition on day 3 of a cytokines mix designed to favour the emergence and multiplication of hematopoietic stem cells (HSC) rather than other mesodermal lineages.
  • HSC hematopoietic stem cells
  • dispersed EBs will adhere to culture surface if permitted to do so, however if this adherence is inhibited by using ultra low adherence surface culture plastic (which do not support cell adherence) there is no detrimental effect on cell numbers (Figure 6), thus this method can be executed completely in suspension culture.
  • HSCs are characterised in part by expression of the CD34 antigen and the maximum of CD34+ cells is generally reached between days 7 and 10, as shown in Figure 7, CD34 can be detected in 30-80% of iPSC or hESC derived cells. Further confirmation of hematopoietic identity is provided by analysis of the CD43 antigen [Ref: Vodyanik MA, Thomson JA, Slukvin II, Blood, 2006 15;108(6):2095-105], as shown in Fig 2, at day 10 flow cytometry analysis shows that 50-100% of cells express this important marker.
  • the antigen expression profile, as well as the rapid Romanovsky staining show that the large majority of the cells are clearly erythroid, with most of them being either pro or basophilic normoblasts.
  • the basal medium is switched to IBIT as Stemline II does not support erythroblast maturation.
  • the corresponding cytokines cocktail has been refined to produce cells which display the highest levels of erythrocytic markers.
  • Cytospins of d24 or d28 cells show a variable distribution between the basophilic, polychromatic and orthochromatic subclasses of erythroblast, depending on the differentiation condition tested and the origin of the hPSCs used (Fig 3 A and B). From this point, when left in the culture conditions described in the methods, the differentiating cells evolve toward an almost homogenous population of orthochromatic normoblasts, with a small percentage of cells undergoing spontaneous enucleation..
  • recombinant Wnt3A could be replaced with small molecule Glycogen Synthase Kinase 3 ⁇ (GSK3P) inhibitors. These drugs were postulated as possible replacements for recombinant Wnt3A because of their ability to mimic sustained Wnt signalling by preventing the phosphorylation of ⁇ -catenin by GSK3P and thereby allowing the release and accumulation of active ⁇ -catenin.
  • GSK3P Glycogen Synthase Kinase 3 ⁇
  • GSK3P inhibitors such as Inhibitor VIII (A-A014418) or CHIR99021 (but not the less specific inhibitor BiO) during day 0 to day 3 of the differentiation protocol could not reproducibly replace Wnt3a.
  • these inhibitors unexpectedly caused a marked improvement in the quality and quantity of erythrocytic cells produced by our differentiation protocol as shown in Fig 3B and 4.
  • In H1 ESC differentiation Inhibitor VIII can replace Activin A but this effect wasn't observed in RC9 and iPSC G cell lines where the absence of Activin A markedly hinders the differentiation efficiency (Fig 9).
  • a GSK3P inhibitor Wnt3A and Activin A in the early stage of differentiation which results in consistent results with all hPSC lines tested (Fig 10 Aand B).
  • the secondGSK3p inhibitor tested, CHIR99021 is more potent (0.2 ⁇ instead of 2 ⁇ for Inhibitor VIII) and has a stronger effect on hESC than hiPSC lines compared to Inhibitor VIII (Table 2). Additionally, increasing the period of treatment with InhVIII (dO to d5) also increases the expansion in cell number.
  • cAMP-dependent protein kinase A plays important roles in many biological processes including proliferation and differentiation in wide variety of cell types and can stimulate cell proliferation by activating ERKs in dividing cells through Ras-mediated activation of either B-Raf or Raf-1 .
  • IBMX 3- isobutyl-1 -methylxanthine
  • IBMX has a synergetic effect on cell amplification (Fig 1 1 A and B, Table 2). IBMX has been tested at various stages of the differentiation protocol and was found to be most effective in inducing maximum amplification when added to culture medium throughout the period day 3 and 17 (Table 2).
  • the cells were also investigated at the molecular level at different timepoints using real time quantitative PCR to evaluate the differences of level of expression of a set of genes involved in hematopoiesis and more specifically, erythropoiesis (Fig 12).
  • Results from either hiPSC or hESC show that small molecules Inhibitor VIII and IBMX increase expression of globin genes and other markers characteristic of definitive hematopoiesis (HBA, HBG, HBB, Runxl , Gata2, HoxB4) as well as genes specific of different stage of erythropoiesis (HOXA9, CD36 and NFE2) and do not affect the necessary reduction in pluripotent markers.
  • the cells are also sturdier and less prone to lysis (Figure 8). These small molecules were tested because of their published properties on CD34+ amplification (SR1 ) or maintenance of pluripotency (SC1 ) (refs below) but they have not previously been implicated in erythroid development. Their effect is strongly dependant of the timing of administration.
  • SR1 CD34+ amplification
  • SC1 pluripotency
  • the method supports a considerable amplification of cell numbers as they differentiate to RBCs (up to 350,000 fold dO-24) which is in excess of previously reported methods, even those using HoxB4 as an amplifying agent [REFS].
  • the method is suitable for either human induced pluripotent stem cells (iPSC) or embryonic stem cells (hESC) referred to together as human pluripotent stem cells (hESC), including hESC lines that have been derived under fully GMP compliant and licensed conditions.
  • the cells reach the orthochromatic normoblast stage of erythropoiesis and display characteristics of definitive hematopoiesis (including the shut off of embryonic globins and expression of ⁇ globin).
  • the protocol starts with hPSC that have been maintained for many passages in feeder-free culture using GMP- compliant reagents amenable to large scale mechanised production.
  • This differentiation method can be used for the efficient differentiation of human pluripotent SC including hiPSC and hESC.
  • This protocol has been optimized using PSC that had previously been maintained on GMP grade cell free substrate (CellStart, Life Technologies) in GMP-grade serum free medium (StemPro, Life Technologies) and unlike many other protocols which use feeder maintained PSC, it is fully compatible with GMP-grade manufacturing.
  • Table 2 table summarizing results obtained when comparing side by side the effect of the addition of GSK3P inhibitors, IBMX or both on the overall amplification of differentiating erythropoietic cultures of hPSCs.
  • the side by side comparison within each experiment allow the assessment of the direct effect of the compound tested without interference from other parameters like quality of initial hPSCs culture, hPCSs passage number, experimenter, activity of cytokines used or other equipment inconsistency. Results consistently show a positive effect of Inhibitor VIII and IBMX. The gain provided by a prolonged period in cytokine mix A is indicated in the coloured columns.

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
EP16702763.0A 2015-01-23 2016-01-22 Zellreifungsverfahren Withdrawn EP3247790A1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1501159.6A GB201501159D0 (en) 2015-01-23 2015-01-23 Cell maturation process
PCT/GB2016/050146 WO2016116769A1 (en) 2015-01-23 2016-01-22 Cell maturation process

Publications (1)

Publication Number Publication Date
EP3247790A1 true EP3247790A1 (de) 2017-11-29

Family

ID=52673854

Family Applications (1)

Application Number Title Priority Date Filing Date
EP16702763.0A Withdrawn EP3247790A1 (de) 2015-01-23 2016-01-22 Zellreifungsverfahren

Country Status (3)

Country Link
EP (1) EP3247790A1 (de)
GB (1) GB201501159D0 (de)
WO (1) WO2016116769A1 (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022539210A (ja) * 2019-07-01 2022-09-07 オロジー バイオサーヴィシズ、インク． マルチパラレルバイオリアクター中で接着性細胞を培養するための方法
US20230174938A1 (en) * 2021-12-08 2023-06-08 Trailhead Biosystems Inc. Methods and compositions for generating human erythroid progenitor cells

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2566561C (en) * 2004-06-04 2013-01-08 Universite Pierre Et Marie Curie - Paris Vi A method for producing red blood cells
GB201212960D0 (en) * 2012-07-20 2012-09-05 Common Services Agency Erythroid production

Also Published As

Publication number Publication date
WO2016116769A1 (en) 2016-07-28
GB201501159D0 (en) 2015-03-11

Similar Documents

Publication Publication Date Title
EP2875126B1 (de) Herstellung von erythroiden zellen
RU2764465C1 (ru) Дифференцировка in vitro плюрипотентных стволовых клеток в панкреатические эндодермальные клетки (пэк) и эндокринные клетки
US11634688B2 (en) Methods and compositions for inducing hematopoietic cell differentiation
Olivier et al. High-efficiency serum-free feeder-free erythroid differentiation of human pluripotent stem cells using small molecules
US9694036B2 (en) Production of midbrain dopaminergic neurons and methods for the use thereof
WO2015065524A2 (en) Suspension and clustering of human pluripotent stem cells for differentiation into pancreatic endocrine cells
EP2938722A1 (de) Aufhängung und gruppierung von menschlichen pluripotenten zellen zur differenzierung in endokrine pankreaszellen
WO2023106122A1 (ja) 間葉系譜への分化に特化した神経堤細胞の製造方法
US20140295552A1 (en) Suspension and clustering of human pluripotent stem cells for differentiation into pancreatic endocrine cells
KR20200051664A (ko) 시험관 내 줄기 세포로부터 유래된 nkx6.1 및 c-펩티드 공발현 세포의 농축
WO2016116769A1 (en) Cell maturation process
JP2023536421A (ja) 多能性幹細胞由来細胞の大規模製造のための閉鎖型製造プロセス
CN102985531A (zh) 涉及由多能干细胞向血细胞分化的培养方法
CN116769695A (zh) 从畸胎瘤、类器官和拟胚体中产生人细胞和组织的培养基和方法
WO2020218579A1 (ja) 分化誘導のために馴化された多能性幹細胞の作製方法
WO2023243627A1 (ja) 胸腺上皮細胞の製造方法
CN118421559A (zh) 定向分化淋巴造血前体细胞的小分子组合、试剂盒及方法
WO2012103098A2 (en) Compositions and methods for treating hematological cytopenias

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20170804

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20180313